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ABSTRACT 
 
Current immune suppressive strategies fail to induce donor-recipient immune tolerance after 
allogeneic hematopoietic cell transplantation. Accordingly, patients suffer morbidity and mortality 
from graft vs. host disease (GVHD) and prolonged immune suppressive therapy. Biologic insight 
into transplantation tolerance is needed, and translation of such insight to novel clinical 
strategies may improve clinical outcomes. We report original investigation at seminal phases of 
this process including initial prophylactic immune suppression, onset of acute graft vs. host 
disease, and ultimate immune suppression discontinuation:  In a controlled randomized clinical 
trial, we demonstrate that sirolimus-based immune suppression reduces risk for acute GVHD, 
ameliorates the severity of subsequent chronic GVHD, and supports reconstitution of functional 
regulatory T cells. Study of tissue-infiltrating CD4+ T cell subsets in acute GVHD target organs 
supports a pathogenic role for Th17 cells. Finally, we demonstrate that peripheral blood 
transcriptional biomarkers provide mechanistic insight into human transplantation tolerance. 
These data signal progress, and suggest rational translational efforts to achieve transplantation 
tolerance. 
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CHAPTER ONE : 
 
INTRODUCTION 
 
Allogeneic hematopoietic cell transplantation and graft vs. host disease: The goal of 
allogeneic hematopoietic cell transplantation (HCT) is cure of malignancy and ultimate 
achievement of donor-recipient immune tolerance. Two major syndromes present the clinical 
manifestation of immune intolerance, namely acute and chronic graft vs. host disease (GVHD). 
Current standard immune suppressive (IS) approaches fail to prevent acute and chronic GVHD 
in most patients, prolonged administration of IS medications is required after HCT, and GVHD 
commonly develops or reocurs upon attempted IS discontinuation. Thus, donor-recipient 
immune tolerance is not effectively induced by current approaches, and consequently patients 
suffer morbidity, disability, and death. These shortcomings speak to the need for further insight 
into the biology of immunologic tolerance and translation of such discoveries to more effective 
immune-modulatory approaches in HCT. The following sections describe current understanding 
of acute and chronic GVHD, and immune tolerance after HCT. 
Acute GVHD is a clinico-pathologic syndrome, which remains a major source of 
morbidity and mortality following HCT. Immunogenetic determinants of acute GVHD include 
disparity between HCT donor and recipient in major and minor histocompatibility antigens,1-3 as 
well as polymorphism in non-HLA genes, including cytokines such as tumor necrosis factor 
(TNF), IL-10, and interferon gamma (IFN-γ),4-6 KIR polymorphism,7,8 and NOD2/CARD15 gene 
polymorphism.9 Pathogenesis has been summarized in multi-phase model. These phases 
include tissue damage from conditioning therapy and activation of antigen presenting cells, 
activation of donor T cells resulting in differentiation and migration, and an effector phase in 
2 
 
which host tissue damage is mediated by inflammatory cytokines including TNF-α and IL-1, and 
effector cells, including cytotoxic T cells.  These inflammatory mechanisms are tempered by 
suppressive factors, including regulatory T cells (Treg). Insight into the biology of the syndrome 
has afforded some advances, but considerable progress is needed.10,11 
Clinically, the syndrome of manifests with erythematous skin rash, cholestatic liver 
disease, and upper or lower gastrointestinal involvement either together or in isolation. Clinical 
severity scoring takes into account severity stage of individual organs, which inform an overall 
grade.12 Clinical predictors of the syndrome include donor relation (greater incidence following 
unrelated donor HCT) and HLA disparity (greater incidence and severity in mismatched HCT) 
between donor and recipient. Investigators have also demonstrated that biomarkers may predict 
acute GVHD and have prognostic ability independent of GVHD severity.13 Importantly, severe 
acute GVHD is associated with refractoriness to glucocorticoid therapy and mortality.14,15 In an 
analysis of 4174 recipients of matched sibling HCT, increasing acute GVHD grade (reference of 
no GVHD) was associated with risk for mortality: grade I, HR = 1.52 (1.19-1.96); grade II, HR = 
2.48 (1.95-3.14); grade III, HR = 5.76 (4.44-7.48); grade IV, HR = 14.7 (10.9-19.9).16 Failure to 
respond to therapy results in poor prognosis: In an analysis of 740 recipients of bone marrow 
allografts with grade II-IV acute GVHD, those with complete response to primary therapy had 
non-relapse mortality (NRM) comparable to those without acute GVHD, whereas NRM 
significantly worsened for those with only partial response, no response, or progressive 
manifestations on therapy.15 Recently, investigators have reported that non-response at 28 days 
following initiation of steroid therapy for acute GVHD was associated with a relative risk (RR) for 
NRM of 2.32 (1.44 – 3.73), p < 0.001, and RR for OS of 2.79 (1.71 – 4.55), p < 0.001 in 
multivariate analysis.  
Clinical investigation has led to some improvement in the prevention of acute GVHD. 
Early efforts established the superiority of combination (cyclosporine and methotrexate) therapy 
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over single agent methotrexate.17 The current standard of care in acute GVHD prevention is the 
combination of tacrolimus and methotrexate. Two large randomized phase III trials 
demonstrated that tacrolimus and methotrexate (TAC/MTX) were superior to cyclosporine and 
methotrexate (CSA/MTX) in the prevention of acute GVHD. Grade II-IV acute GVHD was 
significantly lower with TAC/MTX compared to CSA/MTX in both sibling donor (32% vs 44%; 
p=0.01), and unrelated donor (56% vs 74%; p=0.0002) trials.18,19 However, it is clear that further 
progress is needed: Protection from acute GVHD is incomplete, chronic GVHD remains a 
common problem, and these competing GVHD prevention strategies have not led to important 
differences in achievement of immune tolerance after HCT. As well, toxicity associated with 
methotrexate in particular has led investigators to examine the activity of alternative agents,20 
such as the combination of tacrolimus with either mycophenolate mofetil,21-25 or sirolimus 
(SIR).26-29   
As currently available prophylactic strategies insufficiently prevent GVHD, many will 
require additional immune suppressive therapy for control of the syndrome. The currently 
accepted standard primary therapy consists of high dose (≥ 1mg/kg/day of prednisone, or dose 
equivalent of alternative steroid agent) glucocorticoids. However, only 30-50% of will achieve 
complete resolution of acute GVHD with this standard therapy.14,15,30 Acute GVHD which fails to 
respond to primary therapy is associated with an adverse prognosis. Most available therapeutic 
agents provide resolution in the minority of cases of refractory acute GVHD, and impose 
additional toxicity. These agents broadly include anti-lymphocyte antibodies, immunotoxin-
based agents, agents targeting cytokines including tumor necrosis factor alpha, pharmacologic 
agents including mycophenolate mofetil, pentostatin, and sirolimus, and extracorporeal 
photopheresis (ECP).31 Given the burden of acute GVHD that develops despite the current 
standard prophylaxis regimen, the limited complete remission achieved with glucocorticoids, 
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and the poor outcomes in those with refractory GVHD, there is a clear need for the development 
of a more effective GVHD prophylaxis regimen.  
Evidence for the combination of sirolimus and tacrolimus for prevention of acute 
GVHD:  Evidence suggests that the regimen of sirolimus (SIR)/tacrolimus (TAC) may be 
effective in the prevention of acute graft vs. host disease (GVHD). Investigators from Dana 
Farber Cancer Institute reported low cumulative incidence of grade II-IV acute GVHD (26%, and 
20%, respectively) in two sequential phase II studies of combined SIR/MTX/TAC, and later 
SIR/TAC.26-28 Investigators from City of Hope have also published on their experience with the 
acute GVHD prophylaxis regimen, drawing particular attention to the risk for thrombotic 
microangiopathy.29 Investigators from the Fred Hutchinson Cancer Research Center reported 
contradictory results in two successive GVHD prophylaxis trials utilizing SIR 
(SIR/MTX/cyclosporine (CSA), and SIR/MTX/TAC); both were halted for lack of efficacy and 
toxicity: 77% developed grade II-IV aGVHD, and 42% stopped SIR early on account of toxicity, 
most prominently thrombotic microangiopathy (TMA) or myelosuppression.32 Thus, data 
available at the time of our trial development indicated potential promise for this regimen, 
however randomized comparative data were lacking.   
Activity of sirolimus as sole primary therapy of acute GVHD and as secondary 
therapy of glucocorticoid resistant acute GVHD: In patients with biopsy confirmed grade II-III 
acute GVHD after HCT, SIR induced complete remission (CR) in 50% of cases.33,34 These data 
support the activity of this agent in control of acute GVHD, notably in the absence of 
glucocorticoid therapy. As well, among a series of 34 patients with glucocorticoid-refractory or 
intolerant acute GVHD, SIR induced complete remission in 44% of cases.35 Taken together, 
these reports demonstrate the activity of this agent in GVHD control, and further strengthen the 
rationale for use of SIR in the primary prevention of GVHD. 
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Role of CD4 T helper (Th) subsets in GVHD pathogenesis: Naïve CD4+ T cells 
differentiate into distinct lineages (Th1, Th2, Th17, Treg) under the influence of antigen-
presenting cells and specific cytokine signals (figure 1). These individual lineages have 
important roles in immunity and immune regulation, and a growing body of literature supports 
diverse functional roles in GVHD pathogenesis. Donor Th1 CD4+ T cells have been 
demonstrated to have a central role in acute GVHD.11 In addition, specific Th1 cytokines, 
including IFN-gamma, have been implicated in the development and maintenance of acute 
GVHD.11,36-38 Pre-clinical data has demonstrated the importance of IL-12 in particular.39-41 In 
murine transplantation models, neutralization of IL-12 prevented the development of acute 
GVHD, polarized CD4+ cells toward a Th2 phenotype, and provided long-term protection from 
GVHD.  
 
 
 
Figure 1:  Schema representing CD4 T helper cell differentiation from naïve T cell to Th1, Th2, 
Th17, and regulatory T cell (Treg) lineages. 
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 Th17 cells have been implicated in solid organ allograft rejection and 
autoimmunity,42-46 and emerging evidence implicates Th17 cells in the pathogenesis of GVHD. 
In murine transplantation models, Th17 cells infiltrate target organs, and are sufficient for the 
generation of GVHD.47-49 Data suggest unique contributions of these CD4+ T cell subsets to the 
target manifestations of GVHD,50 and the relative balance of CD4+ subsets appears to be 
important. Loss of Treg and expansion of donor Th1 and Th17 CD4+ T cells was associated 
with the release of inflammatory cytokines, and autoimmune manifestations of chronic GVHD in 
one model.51  In addition, investigators have identified secretion of IL-23 by antigen-presenting 
cells to be an essential component of GVHD induction,52 indicating the relevance of this 
cytokine in particular as a therapeutic target. Simultaneous blockade of Th1 and Th17 (through 
targeted disruption of T-bet and RORγt transcription factors) prevented GVHD in a major MHC 
mismatched murine model, and did not impair graft-versus-leukemia (GVL) activity.53 These 
data implicate both Th1 and Th17 CD4 lineages in the pathogenesis of acute GVHD, and thus 
identify these as potential targets of novel therapeutic approaches. 
 Regulatory T cells (Treg) are a naturally occurring subset of T cells that are 
distinguished by their constitutive expression of CD25, and expression of transcription factor 
FoxP3.54-56 They are potent suppressors of immune responses, and therefore, have potential 
application in the prevention and treatment of GVHD. Treg suppress alloreactive T cells in vitro 
and prevent lethal acute GHVD in MHC-mismatched allogeneic transplantation models.57-60 
Given the low frequency (< 5%) among human T cells, several groups have performed ex-vivo 
expansion for therapeutic applications. Accordingly, translation to human clinical trials has 
become more feasible.55-57,61-68 Ex-vivo expanded Treg demonstrate increased suppressive 
potency.69,70 As well, antigen-specific Treg achieve selective suppression of allo-responses with 
no suppression of third-party responses.71-78 In experimental systems, Treg appear to abrogate 
GVHD, while preserving graft vs. leukemia (GVL) responses.79,80 This is a critical consideration 
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in the application to human studies, as the major goal of HCT is often control of malignancy. 
Pre-clinical data support that SIR supports the expansion and suppressive function of Treg; 
conversely, calcineurin inhibitors including CSA and TAC, have an adverse impact on regulatory 
T cell survival and function, given their interference with IL-2 production.81-83   
 Thus, current pre-clinical evidence implicates Th1 and Th17 in GVHD pathogenesis, and 
support the potent immune regulatory role of Treg. Human clinical evidence largely supports this 
paradigm: HCT recipient peripheral blood,84-86 and donor graft,87,88 Treg frequency has an 
inverse relationship with the occurrence and severity of GVHD, and resultant risk for mortality.89 
Donor allograft Th17 numbers have been associated with acute GVHD following HCT,90 and 
Th17 have been associated with inflammatory bowel disease.91 Studies in GVHD target organ 
tissues suggest a predominance of Th1 and not Th17 cells in cutaneous GVHD.92 Th17 have 
been implicated in intestinal GVHD,93 as well as inflammatory bowel disease,94 and allied 
immune-mediated disorders.46,95  FoxP3+ Treg in cutaneous GVHD,96 as well as 
FoxP3+Treg/CD8+ T cell ratio in acute and chronic GVHD,97 have an inverse relationship with 
GVHD and its severity. Thus, while discrepant findings have been reported,98,99 this overall 
paradigm suggests targeted approaches to deplete Th1/Th17 and augment Treg may mitigate 
risk for GVHD after human HCT.  
 Sirolimus suppresses alloreactive T cells, inhibits differentiation of Th17 cells from 
naïve CD4 T cells, and promotes generation of Treg: Sirolimus (SIR), or rapamycin, is a 
naturally occurring inhibitor of mammalian target of rapamycin (mTOR). Treatment with SIR 
leads to inhibition of transcription and decreased kinase activity of cyclin-dependent enzymes.  
SIR also inhibits dendritic cell development and function. In T cells, SIR produces at least partial 
blockade of CD28 mediated co-stimulatory signaling. However, SIR is permissive for Treg: SIR 
permits expansion of Treg, preserves the potent CD27+ subset of Treg, does not impair Foxp3 
expression, and allows for greater suppressor function as compared to Treg treated with CSA.81-
8 
 
83,100-102 While effector T cells are sensitive to the inhibitory effect of SIR, Treg expand. Treg in 
murine and human systems do not activate the phosphatidyl inositol 3-kinase (PI3-K)/AKT 
pathway after activation through the T cell receptor. As SIR inhibits mTOR in this pathway, it 
may selectively inhibit effector T cells.100,103,104 As well, SIR inhibits differentiation of naïve CD4 
T cells to Th17, and promotes generation of Treg.105 Thus, SIR may favorably modulate the 
immune system and mitigate GVHD risk and promote immune tolerance. 
 Chronic graft vs. host disease:  Chronic graft-versus-host disease (GVHD) is a major 
long-term problem after HCT. The syndrome is associated with significant morbidity, mortality, 
impaired quality of life (QOL), greater symptom burden, and prolonged duration of immune 
suppressive therapy following HCT.106-115 Pre-clinical and clinical observations suggest some 
insight into the pathogenesis of the syndrome, but much remains to be elucidated. Prevailing 
hypotheses suggest that chronic GVHD may be driven by alloreactive donor T cells and 
countered by regulatory T cells,84,116-119 loss of tolerance,120 altered B cell homeostasis, 121-124 
and activation of pro-fibrotic pathways.125,126 Chronic GVHD occurs in the majority of patients at 
risk, up to 60-80% of those who survive more than 100 days after transplantation.108,109 The 
syndrome is characterized by diverse manifestations; the most commonly occurring 
manifestations arise in the skin, eyes, mouth, and liver. Major changes in the classification and 
severity grading of the syndrome have been suggested by the NIH Chronic GVHD Consensus 
Conference,127 and severity has been validated as a determinant of survival.128 Risk factors for 
development of chronic GHVD include increasing age of the donor or recipient, donor/recipient 
HLA disparity and donor relation, male recipients of allografts from alloimmunized female 
donors, prior occurrence of acute GVHD, and the use of peripheral blood mobilized stem cells 
vs. bone marrow.116,129-131  
 Importantly, the majority of approaches for initial GVHD prevention have failed to alter 
the incidence or severity of chronic GVHD.18,19,28 One major exception – ex-vivo T cell depletion 
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from allografts – is complicated by risk for poor immune reconstitution and serious infections 
after HCT, as well as malignancy relapse. Others have attempted to decrease risk for chronic 
GVHD development through prolonged administration of calcineurin inhibitor after HCT, 
however these studies have failed to show any consistent benefit.132-135 Thus, most will 
experience the syndrome, and therapy is often required to control symptoms and prevent 
progressive organ damage from chronic GVHD. Systemic steroid treatment is required to 
control established moderate-severe chronic GVHD, and 1mg/kg/day of prednisone remains the 
standard initial therapy. Trials examining novel combination therapies (prednisone in 
combination with either azothioprine, thalidomide, hydroxychloroquine or mycophenolate 
mofetil) have not shown benefit.136-139 Complete resolution of chronic GVHD following initial 
therapy, however, is limited (by 6-9 months of prednisone therapy, complete response occurs in 
30%, and complete + partial response occurs in only 60%).136-139 Most patients will require 
additional lines of immune suppressive therapy to control chronic GVHD, and outcomes of 
secondary (and beyond) therapy for chronic GVHD are poor; a recent major analysis suggests 
that failure-free survival (i.e. freedom from death, malignancy relapse, and treatment change) 
for such patients is only 31% by 2 years, and 25% by 4 years after initiation of secondary 
therapy.140 Thus, chronic GVHD is a major obstacle to the success of HCT, and novel strategies 
to prevent the syndrome are needed. 
 Development of immune tolerance following HCT – Biologic Mechanisms: 
Experimental evidence demonstrates that multiple cellular and molecular mechanisms actively 
support the state of immune tolerance.141-144 T cells have a central role, including induction of T 
cell anergy 145-147, central (thymic) and peripheral deletion,148 mixed chimerism,149-154 external 
influences including Treg,54,59,155-159 the balance of cytopathic and regulatory T cells,160 and co-
stimulatory molecule signaling.161-166 Several other important mediators of immune  tolerance 
include dendritic cells,167,168 B cells,169 and components of the innate immune system, 
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importantly including NK cells.170 Based on central findings from the investigation later 
presented, the following content focuses on dendritic cells, NK cells, and evidence surrounding 
their cooperation in immune tolerance. 
Dendritic cells, professional antigen-presenting cells, sense environmental signals and 
orchestrate competing immune responses: Pro-inflammatory responses (up-regulation of HLA, 
co-stimulatory molecules, and inflammatory cytokines) drive antigen-specific responses of the 
adaptive immune system. Ligation of toll-like receptors (TLR) and downstream signaling 
(MyD88, TRIF, NFkB) result in up-regulation of co-stimulatory molecules and pro-inflammatory 
cytokines.171  In contrast, a coordinated tolerogenic program (reduced co-stimulatory molecules 
and pro-inflammatory cytokines, and elaboration of tolerogenic signals including IL-10, IDO, 
TGF-β, among others) promotes T cell anergy, deletion, and induction of regulatory T cells 
(Treg).  
NK cells are major components of the innate immune system that mediate killing of 
virally infected and malignant cells, and regulate other immune cells through elaboration of 
cytokines and chemokines. NK cells express multiple activating and inhibitory cell surface 
receptors, and the integration of these signals directs NK cell function.172 Numerous killer 
immunoglobulin-like receptors (KIR) have been described, and KIR/KIR-ligand mismatch have 
been identified as key in NK licensing/education, and killing of allogeneic targets.172 In the 
setting of HLA mismatched haploidentical HCT, this mechanism is central to alloreactive donor 
NK killing of recipient DC, facilitation of donor engraftment, and effective control of 
malignancy.173 Additional NK cell receptors include natural cytotoxicity receptors (NCR) and 
lectin receptors (heterodimers of CD94:NKG2 family members).  The CD94/NKG2 complex is 
expressed on NK and T cells. NKG2C and NKG2A interact with the non-classical MHC class Ib 
molecule, HLA-E, which presents peptides derived from sequences of other HLA class I 
molecules (while NKG2D interacts with ULBP, MICA, and MICB). Generally, NKG2C/D/E/F 
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have been classified as activating receptors, while NKG2A has been deemed inhibitory. 
However, diverse functional roles have been demonstrated for NKG2A:  Qa-1 (the murine 
homologue of HLA-E) – together with Qdm – is expressed on activated CD4+ T cells. Qa-1 
binding to TCR activates and expands antigen-specific CD8+ T cells. Conversely, Qa-1 binding 
to NKG2A/CD94 on CD8+ T cells, NK, and NKT leads to reduced activation of these cells. Qa-1 
on activated CD4+ T cells has divergent interactions with NK and CD8+ Treg: Engagement of 
CD94/NKG2A on NK cells protects CD4+ T cells from lysis, while engagement of TCR on Qa-1 
restricted CD8+ Treg leads to expansion of these CD8+ Treg and suppression of CD4+ T cell 
activation.174  NKG2A in human γδ T cells inhibits NKG2C based effector function.175 NKG2A 
signaling has been reported to have tolerogenic activity: Human NK-hepatocyte interaction via 
NKG2A led (through TGF-β) to DC-mediated induction of CD4+CD25+ Treg that suppressed T 
cell activation through PD-1/PDL-1 interaction.176 As well, a NK subset identified in lymph nodes 
expressing CD94/NKG2A but not KIR controlled self-DC activation through killing of immature 
DC.177  
NK can promote immune responses through promoting DC maturation and cytokine 
production through NK-DC interaction, promote Th1 polarization of CD4+ T cells via IFN-γ, 
promote cytotoxic T cell responses, promote B cell isotype switching through IFN-γ, and 
augment inflammatory responses executed by monocyte and macrophages.178-180 NK cells have 
been implicated in both autoimmunity and solid organ transplant rejection.180-185 In contrast, NK 
cells have a major role in immune regulation. Major proposed mechanisms have included 
production of IL-10, competition with CD8+ T cells for IL-15, killing of dendritic cells (in particular 
immature DC), and killing of activated T cells.180,186-192 As well, NK cells are predominant in 
tolerant organs (e.g. liver, lung, intestine, and uterus),178 have  a central role in maternal-fetal 
tolerance (through regulation of Th17,193 and expansion of Treg),194 mitigate allograft rejection in 
experimental models,180 appear to be central mediators of transplantation tolerance in human 
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hepatic allografts,195 may exert a protective function in a number of autoimmune disorders,196-199 
and their deficiency is a risk factor for chronic GVHD development after HCT.200  
Bi-directional interaction between DC and NK cells leads to activation and cytokine 
production, DC maturation, and NK proliferation and cytotoxicity.179,201 DC promote NK 
activation, cytokine secretion and survival through multiple mechanisms: DC produce IL-15, 
which is essential for NK survival and differentiation;202 DC also produce IL-12, which enhances 
NK cytotoxicity and IFN-γ production,203 as well as IL-1 and IL-18, which potentiate the effect of 
IL-12 through induction of IL-12R on NK cells; DC also stimulate antigen-specific T cells which 
secrete IL-2 and activate NK;204 DC and T cells also up-regulate ligands (e.g. MICA and MICB 
for NKG2D)  for NK receptors. In turn, NK stimulate DC through cytokine (TNF, IFN-γ, GM-CSF) 
production, and NKp30-NKp30 ligand interaction.179  In contrast, NK can also kill DC, and this is 
thought to be dependent upon NKp30 and NKp46 receptor ligation.205-207 Immature DC are the 
primary target of NK cell killing: Both mature and immature DC express surface HLA class I 
molecules, but the surface density is increased in mature DC.177 One hypothesis to explain the 
selection of NK stimulation of DC maturation vs. NK killing of DC is based on the ratio of NK to 
DC in experimental systems: With high NK:DC ratio, NK kill immature DC. In contrast, with low 
NK:DC ratio, DC maturation and cytokine (IL-12, TNFα) production is increased.208 
Finally, emerging evidence supports the presence of NK cell subsets that may have 
divergent functional roles. One major sub-grouping is based on CD56 expression: While most 
human peripheral blood NK cells are CD56dimCD16+, approximately 10% of human peripheral 
blood NK cells are CD56brightCD16-. In contrast, CD56brightCD16- NK cells are enriched in 
tolerant organs, including human liver and uterus. These CD56brightCD16- NK cells may have an 
immunoregulatory role, and have been shown to control autoimmunity in part through APC-
derived IL-27 driving NK cell IL-10 secretion.209,210 CD56brightCD16- NK cells express high-affinity 
interleukin-2 (IL-2) receptor which enables them to proliferate and produce IFN-g in response to 
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low doses of IL-2, express CD94:NKG2A  but low KIR (CD94:NKG2A+KIR- phenotype), and 
express lymph node homing molecules L-selectin, CXCR3 and CCR7. CD56bright NK cells with 
constitutive expression of high-affinity (IL-2Rαβγ) IL-2 receptor are present in human lymph 
nodes, stimulated by endogenous T cell derived IL-2, and secrete IFN-γ.204 Human 
CD94/NKG2A+KIR- NK cells can kill autologous (primarily immature) dendritic cells, while NK 
cells that express KIR specific for self HLA class I do not kill autologous DC.177  Multiple 
additional regulatory NK cell subsets have been identified, many of which produce established 
immunoregulatory cytokines including IL-10 and TGF-β.178 Several have been identified as 
protective in auto-immune disorders including type I diabetes and multiple sclerosis. Thus, a 
growing body of experimental and human data demonstrates the toleragenic capacity of NK, 
and the importance of DC-NK cooperation. 
Development of immune tolerance following HCT – Investigation into human 
transplantation tolerance biomarkers: Clinically, immune tolerance after transplantation has 
been defined by no ongoing immunologic injury due to incompatibility between donor and 
recipient following discontinuation of immune suppressive (IS) therapy.211-213 While allograft 
rejection constitutes the major manifestation of immunologic injury in solid organ transplantation, 
acute and later chronic graft vs. host disease represent the major challenges after HCT. 
 In the setting of both solid organ transplantation and HCT, clinical judgment does not 
distinguish drug-suppressed immune response from development of immune tolerance. Thus, 
discontinuation of immune suppression (IS) is associated with serious risks, and individualized 
practice is not possible. There has been great interest in defining biologic markers of immune 
tolerance that may ultimately permit individualized management of IS. Investigators have 
reported changes in gene expression associated with the tolerant clinical phenotype in solid 
organ transplantation.195,214-216 While there are potential challenges in the direct comparison of 
these studies, changes in gene expression in tolerant individuals recapitulate mechanisms of 
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immune tolerance supported by previous experimental evidence: One nearly consistent finding 
across these studies is that of reduced expression of genes important for immune activation and 
response, overall depicting a state of immune quiescence. Of particular importance in Brouard, 
et al are genes reflecting reduced immune response, apoptosis, and growth arrest that have 
been demonstrated to be under the control of TGF-β. Supporting another major mechanism of 
immune tolerance, Brouard, et al demonstrated decreased expression of genes related to co-
stimulatory signaling.214 Additionally, several of these reports support the importance of Treg: In 
the tolerant subjects, Brouard reported increased FOXP3 expression, Martinez-Llordella 
described increased Treg by immunophenotyping, and Kawasaki reported increased expression 
of STAT1, which has importance in Treg development.214,216,217 Not specifically supported by the 
other studies, Martinez-Llordella demonstrated increased numbers and enrichment for genes 
expressed by γδT cells, enrichment for genes expressed by NK cells, and a polarization toward 
Vγδ1+ subtype predominance among the γδT cell population.217 Thus, these efforts have begun 
to signal progress in the field. 
 Investigation into tolerance associated gene expression in solid organ transplantation 
has limited practical application, as the majority of solid organ transplant recipients require life-
long IS. Conversely, these applications have great relevance in HCT, as most patients 
eventually discontinue IS therapy. However, IS discontinuation practice is empiric and often met 
with flares of graft vs. host disease and subsequent escalation in IS.218 This makes clear an 
unmet need for an understanding of tolerance mechanisms, and an informed, rational approach 
to IS discontinuation after HCT. 
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CHAPTER TWO: 
 
METHODS 
 
 
 Randomized phase II study to evaluate tacrolimus in combination with sirolimus or 
methotrexate after allogeneic hematopoietic cell transplantation:   
 
 Study design: We conducted a prospective, randomized comparison of sirolimus 
(SIR)/tacrolimus (TAC) vs. methotrexate (MTX)/TAC (NCT00803010).  This trial was approved 
by the University of South Florida Institutional Review Board. Randomization was stratified for 
age (> 50 vs. age < 50), and donor type (sibling vs. unrelated); these two factors were selected 
for stratification based on existing evidence supporting their impact on risk for GVHD. All 
patients received peripheral blood mobilized grafts. The primary objective of this trial was to 
evaluate the efficacy of SIR/TAC vs. MTX/TAC in prevention of grade II-IV acute GVHD.  The 
study was powered to detect difference in the incidence of grade II-IV acute GVHD between 
SIR/TAC and MTX/TAC treated patients. Among MTX/TAC treated patients, we anticipated 
grade II-IV acute GVHD of 80%, based on that observed in MTX/TAC treated patients on a prior 
prospective clinical trial at our center.219 Based on previously published single-arm phase II 
SIR/TAC trial results which demonstrated approximately 20% incidence of grade II-IV acute 
GVHD in comparison to previously reported incidence of 40-50% following MTX/TAC,27,28 our a 
priori hypothesis was that we would observe a 50% reduction in this primary endpoint. With 56 
evaluable patients without competing-risks, two-sided log-rank test would achieve 90% power at 
0.1 significance level. We anticipated 20% of evaluable patients would develop competing-risk 
events within 100 days, and adjusted the total sample size to 70. We increased the sample size 
to 74 (37 in each arm) for possible 5% dropout.  
16 
 
 Patients: Included patients were age 16 – 70 with cardiac ejection fraction ≥ 45%, 
FEV1, FVC, and DLCO ≥ 50% predicted values, AST and ALT < 3 times upper limit of normal, 
creatinine clearance ≥ 50 cc/min, and Karnofsky Performance Status ≥ 60%. Included disease 
were the following: Acute myelogenous leukemia of intermediate/high risk in first complete 
remission (CR1), or beyond CR1; myelodysplastic syndrome with IPSS score of ≥ 1.5; 
myeloproliferative disorders; chronic myelogenous leukemia; acute lymphoblastic leukemia; 
chronic lymphocytic leukemia; severe aplastic anemia; multiple myeloma; and Hodgkin or non-
Hodgkin lymphoma. Patients with hepatitis B or C, human immunodeficiency virus (HIV), 
uncontrolled systemic infection, or HCT-comorbidity index ≥ 3 were excluded.220  
 Treatment protocol: Eligible donors were sibling or unrelated donors matched at HLA-
A, B, C, and DRB1 by high-resolution typing.  G-CSF mobilized peripheral blood products were 
targeted to a CD34+ cell dose/kg of 5-10 x 106.  Use of anti-lymphocyte antibodies and 
cyclophosphamide-containing regimens was prohibited, but the conditioning regimen was 
otherwise not mandated. Institutional standards for bacterial, viral, and fungal infectious 
prophylaxis and monitoring were followed.  
 GVHD prophylaxis: TAC was administered from day -3 at 0.02mg/kg/day, then 
transitioned to oral formulation before hospital discharge. For patients receiving MTX, serum 
TAC target was 5-15 ng/mL. When given concurrently with SIR, target TAC was 3-7 ng/ml. 
According to protocol, patients without evidence of acute GVHD and not on therapy with 
systemic glucocorticoids were eligible to being TAC taper at day 50 following HCT. SIR was 
administered as a 9 mg oral loading dose on day -1, followed by maintenance to target 5-14 
ng/ml. The protocol mandated that SIR should be continued through at least 1 year post-HCT. 
We aimed to determine if this prolonged course of SIR would impact risk for chronic GVHD 
development, severity, and ultimate discontinuation of all immune suppression. MTX was 
administered on day +1 at 15 mg/m2, and then 10 mg/m2 on days 3, 6, and 11. Beyond the 
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above specifications, the protocol did not mandate a particular taper schedule for TAC, SIR, 
systemic glucocorticoids, or other immune suppressive agents.  
 Study endpoints: Neutrophil and platelet engraftment were defined by standard 
methods. Mucositis was graded per CTC version 4.0. Diagnosis and severity grading of 
thrombotic microangiopathy (TMA) adhered to BMT Clinical Trials Network consensus.221 
Hepatic veno-occlusive disease (VOD) was diagnosed according to standard clinical criteria.222 
Acute GVHD was scored weekly from HCT to day 100; in keeping with established clinical 
practice, biopsy confirmation of acute GVHD was not required by the protocol.12  However, 
biopsies were obtained according to usual practice when deemed necessary by treating 
clinicians. These GVHD biopsies were reviewed by Pathologists blind to study arm assignment. 
Chronic GVHD was scored per NIH consensus criteria.127 Peripheral blood sorted (CD3 and 
CD33) and bone marrow donor chimerism were assessed at days 30, 90, 180, and 360 by PCR. 
Disease restaging occurred on days 30, 90, 180, and 360, 18 months, and 2 years following 
HCT. Patient reported quality of life (QOL) was assessed using the Functional Assesment of 
Cancer Therapy – Blood and Marrow Transplantation (FACT-BMT) questionnaire at baseline 
pre-HCT, and on days 30, 90, 180, 270, 360, 560, and 740 post-HCT.223  
 Treg repopulation post-HCT and suppressive function: Samples were drawn from 
peripheral blood of HCT recipients at the following time points: Baseline (prior to beginning 
conditioning regimen and HCT); day 0, 30, 90, 180, and 360 after HCT. Peripheral blood 
mononuclear cells (PBMC) were isolated by Ficoll-hypaque gradient centrifugation. PBMC were 
stained with labeled antibodies (CD3PerCp, CD4FITC, CD25PE, CD127Alexa 647 and mouse 
IgG1 isotype controls from BD Biosciences). Samples were analyzed using FACS Calibur flow 
cytometer with CellQuest software (BD Immunocytometry Systems, San Jose, CA). T cells were 
identified by gating on CD3+ and CD4+ populations, and Treg were defined by CD4+, 
CD25(bright),  and CD127(negative) phenotype.  The reciprocal relationship between negative 
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surface CD127 and high intracellular FoxP3 expression was confirmed in a subset (n=15) of day 
30 patient samples (r=0.94).  
 The suppressive potential of Treg was examined in a subset from both SIR/TAC and 
MTX/TAC groups from blood cells obtained between 90 and 180 days after HCT. 
CD4+CD25+CD127- Treg were isolated on a BD FACSAria II high-speed cell sorter (BD 
Biosciences, SanJose, CA).  Treg were added in different ratios to 1 x 104 self CD4+CD25- T 
responder cells in the presence of 1:1 CD3/CD28 beads (Invitrogen Corporation, Carlsbad, CA) 
in 96-well round-bottom plates.  Proliferation was analyzed by [3H] thymidine incorporation using 
a gas scintillation counter (Matrix 96 beta counter, Canberra Packard, Meriden, CT).  Cells were 
pulsed with 1μCi/well 3H-thymidine for the last 18 hours in culture and harvested on day 5 to 
measure proliferation.  Results are expressed in counts per minute (CPM) of triplicate 
measurements. 
 Statistical methods: The intent-to-treat population was used to conduct all analyses for 
all endpoints. Cumulative incidence of grade II-IV aGVHD was estimated and compared by the 
Gray test.224 Survival was analyzed using the Kaplan-Meier method and compared using the 
log-rank test. Cumulative incidence of non-relapse mortality and relapse were estimated and 
compared. Pointwise 95% confidence intervals for survival curves and cumulative incidence 
curves were computed using log-log transformation. Analysis of association between GVHD 
outcomes and time-dependent measures (serial TAC and SIR levels, serial measures of Treg) 
utilized Cox regression model with time-varying covariates.  Two-sided Wilcoxon rank-sum test 
was employed to test difference in percent Treg (% Treg/total CD4+ cells) on day 30, 90, 180 
and 360 at significance of 0.05 (alpha of 0.025 at each time point using Bonferroni-Holm 
adjustment).  
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 Tissue-infiltrating Th1, Th17, and Treg in GVHD target organs following human 
allogeneic hematopoietic cell transplantation: 
 
 
 Included patients: Patients were randomized to SIR/TAC or MTX/TAC on trial  as 
described above.225 Acute GVHD severity was scored per standard criteria weekly from HCT to 
day 100.12 Those cases with GVHD who had diagnostic biopsy performed (including skin, 
gastrointestinal tract, or liver) were identified for this analysis. Pathologic GVHD grading was 
performed according to standard criteria with the Pathologist blind to study arm.  
 Processing and staining of GVHD tissue samples: Biopsies were preserved in 
neutral buffered formalin and processed in usual manner. Cylindrical punches were removed 
from paraffin-embedded tissue blocks to create a tissue microarray (TMA). Tissue microarray 
was utilized to improve experimental uniformity and ensure highly parallel analysis.  Antibodies 
to RORγ (rabbit, 1:300 Abcam, Cambridge, MA), T-bet (mouse, 1:25, BD Biosciences, San 
Jose, CA), FoxP3 (mouse, 1:25, Abcam, Cambridge, MA) and CD4 (rabbit, 1:25, Cell Marque, 
Rocklin, CA) were utilized for immunohistochemistry (IHC) studies. Slides were stained using a 
Ventana Discovery XT automated system (Ventana Medical Systems, Tucson, AZ) per 
manufacturer’s recommendations with proprietary reagents. Individual 4 µm sections were 
transferred to positively charged slides.  The slides were deparaffinized on the automated 
system with EZ Prep solution (Ventana).   Following heat-induced antigen retrieval methods in 
Cell Conditioning 1 (Ventana) for FOXP3 and T-bet and in RiboCC (Ventana) for CD4 and 
ROR-gamma, the samples were incubated with the selected antibodies using Dako antibody 
diluent (Carpenteria, CA).  Then the Ventana UltraMap Anti-mouse secondary antibody was 
utilized for FOXP3 and Tbet, while the Ventana UltraMap Anti-rabbit secondary antibody was 
utilized for CD4 and ROR-gamma.  Ventana ChromoMap kit detection system was used and the 
slides were then counterstained with hematoxylin.  Finally the slides were dehydrated and 
coverslipped per normal laboratory protocol. Stained slides were scanned using Aperio™ (Vista, 
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CA, USA) ScanScope XT with a 200x/0.75NA objective lens at a rate of 3 minutes per slide via 
Basler tri-linear-array. Positivity for each marker was quantitatively scored using the TMA 
module of the TissueStudio v3.0 software platform from Definiens (Munich, Germany) for each 
TMA core (0.6mm diameter, or 1.13mm2 area). Staining intensity thresholds were held constant 
throughout the study. In a subset of 10 randomly selected TMA cores, contiguous sections (4m 
thickness) were stained with CD4 and RORγ for co-registration analysis; based on high degree 
of co-registration of CD4 and RORy, we elected to only utilize RORy to identify Th17 cells. T-bet 
was utilized to identify Th1, and FoxP3 identified Treg.  
 Statistical methods: Data are presented as absolute numbers for each CD4 subset 
(Th1, Th17, Treg), and ratio of each to total CD4+ cells. Analysis of variance (ANOVA) was 
utilized to compare tissue lymphocyte numbers according to clinical grade, pathologic grade, 
and GVHD prophylaxis group. Logistic regression analysis was used to study the association 
between tissue lymphocyte numbers and response to primary GVHD systemic glucocorticoid 
therapy; due to limiting number of events, only univariate relationships are described for this 
analysis.  
 
 
 
 Tolerance associated gene expression following allogeneic hematopoietic cell 
transplantation: 
 
 
 Identification of study patients and control subjects: From long-term survivors of 
allogeneic hematopoietic cell transplantation (HCT) in the Moffitt Cancer Center Blood and 
Marrow Transplantation Program, tolerant patients (TOL) were identified. The tolerant 
phenotype was defined by successful discontinuation of all IS agents (minimum time from 
complete discontinuation of IS to time of sample acquisition of 6 months), and sustained 
absence of any detectable clinical, radiographic, or laboratory manifestations of acute or chronic 
graft vs. host disease. The absence of manifestations of graft vs. host disease was confirmed by 
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at minimum two transplant physicians in each case to determine eligibility. Through systematic 
search of the program database including all allogeneic transplant recipients, matched non-
tolerant comparator subjects (non-TOL) were identified who were not able to successfully 
liberate from immune suppression due to graft vs. host disease. An algorithm was developed 
wherein non-tolerant comparators were matched to the individual tolerant cases by date of HCT 
(+/- 6 months) and age at time of HCT (+/- 5 years). From all non-tolerant comparators for each 
case that met criteria, the best matched non-tolerant comparator was selected according to 
identity on the following factors in descending rank order: HLA matching between HCT donor 
and recipient (identical at HLA-A, -B, -C, and –DRB1 vs. mismatch), donor relation (sibling vs. 
unrelated donor), stem cell source (peripheral blood vs. bone marrow), GVHD prophylaxis 
agents, disease requiring transplantation, and conditioning regimen. Healthy volunteers were 
recruited to serve as control subjects. Minimum demographic information (age, gender) was 
collected, and volunteers completed a brief medical questionnaire to confirm they were not 
acutely ill for any reason, had no chronic medical conditions and were not taking any 
medications. These healthy control subjects were of interest, as they had not received HCT and 
were not treated with immune suppressive agents. All patients provided informed consent for 
participation in the study, which was approved by the University of South Florida Institutional 
Review Board. 
 Assessment of clinical data: For all participating tolerant and non-tolerant HCT 
recipients included in the study, standardized medical record abstraction was performed. 
Baseline demographic and transplantation variables included the following: age at time of HCT, 
condition requiring HCT, remission status at time of HCT, stem cell source, CD34+ cell dose/kg 
body weight, donor relation, donor age, gender matching of donor and recipient, HLA matching 
at HLA-A, -B, -C, and –DRB1 loci, cytomegalovirus serologic matching between donor and 
recipient, conditioning regimen, and GVHD prophylaxis agents utilized. Comprehensive 
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information was gathered on prior manifestations of acute and chronic GVHD including the 
following: Initiation and discontinuation dates of all immune suppressive agents (with indications 
for tapering and discontinuation of each agent) including both original prophylaxis agents, and 
those later employed for therapy of acute and chronic GVHD; onset, peak grade, biopsy 
confirmation, therapy delivered, resolution date, and recurrent manifestations for both acute and 
chronic GVHD;12,127 outcome data including relapse date, date of death, and dates of last clinical 
follow up; and finally date of discontinuation of all systemic immune suppressive agents.  
 Sample processing, cell subsets and microarray analysis: Each subject consented 
to peripheral blood collection, which included two 10cc EDTA tubes. Freshly acquired samples 
were immediately processed. From one sample, peripheral blood mononuclear cells (PBMC) 
were isolated using the Ficoll-Hypaque method, and were immediately processed for 
characterization of cell phenotype by flow cytometry. PBMC were stained with labeled 
antibodies: T cell panel (CD3-Percp5.5, CD8αβ-FITC, CD8αα-PE, CD4-Alexa700, CD25-PE-
Cy7, CD127-Alexa647); NK, B cell, and monocyte panel (CD3-Percp5.5, CD16-Alexa700, 
CD56-PE, CD19-PE-Cy7, CD14-FITC); Dendritic cell panel (HLA-DR-Percp-Cy5.5, Lin1-FITC, 
IL-3Ra (CD123)-PE, CD11c-APC). All antibodies were from BD Biosciences, except live/dead-
yellow (Invitrogen). Red blood cells were lysed, samples washed, and samples were analyzed 
using the LSR II flow cytometer (BD Biosciences). We quantified immune cell subsets according 
to the following phenotypic markers: total CD4 T cells (CD4+); total CD8 T cells (CD8+); αβ CD8 
T cells (CD8+, αβ TCR+); αα CD8+ cells (CD8+, αα TCR+); Treg (CD4+,CD25+,CD127(low)); 
NK cells (CD16+, CD56+); B cells (CD19+) ; monocytes (CD14+); type 1 Dendritic cell (HLA-
DR+, CD11c+, Lin-); type 2 Dendritic cell (HLA-DR+, IL-3Rα+, CD4(low), CD11c-, Lin-). Due to 
multiple comparisons, we utilized a pre-defined level of significance (p < 0.01) for comparisons 
between groups. 
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PBMC were similarly isolated from the second sample, and total RNA was extracted to 
serve as the mRNA source for microarray analysis. RNA extraction was performed using the 
RNAeasy Mini Kit (Qiagen), and RNA was quantified using a NanoDrop 1000 
spectrophotometer. The RNA quality was assessed using an Agilent 2100 Bioanalyzer. The 
poly(A) RNA was converted to cDNA, then amplified and labeled with biotin following the 
procedure initially described by Van Gelder et al.226 Hybridization with the biotin labeled RNA, 
staining, and scanning of the chips followed the procedure outlined in the Affymetrix technical 
manual.227 All analyses used the Affymetrix Human U133 plus 2.0 array, which contains 
approximately 48,000 probe sets designed from GenBank, dbEST, and RefSeq sequences 
clustered based on build 133 of the UniGene database and an additional 6500 transcripts 
identified from Unigene build 159. Scanned output files were visually inspected for hybridization 
artifacts and then analyzed by using robust multi-array average analysis (RMA). RMA is a well-
established procedure that uses quantile normalization and a model-based signal calculation for 
determination of expression values in probe-based microarray gene expression.228  
 Statistical methods: Following the approach proposed in Tibshirani, et al, we used the 
SAM software to generate an estimate of power.229 We utilized PBMC data run on the same 
platform (Affymetrix HG-U133Plus 2.0) from liver transplant patients in Martinez-Llordella, et al 
to generate estimates for sample size and power.195 Using 10 TOL and 10 non-TOL liver 
transplant patients, and false discovery rate (FDR) of 10%, we estimated 99% power to detect 
an effect size of 1.5 for differentially expressed genes, assuming there are approximately 233 
truly significant genes. Thus, we projected a minimum sample size of 20 total subjects.  
The Significance Analysis of Microarrays (SAM) technique of Tusher, et al was 
employed to identify differentially expressed genes between phenotypic groups.230 SAM was 
utilized for the two group (TOL vs. non-TOL) comparison with 10% FDR, and ≥ 1.5 fold 
difference in mean expression values. To account for confounding by immune suppression 
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(absent in TOL vs. present in non-TOL cases), we employed the following analyses:  We first 
utilized SAM to identify differentially expressed genes between TOL and non-TOL groups. 
Second, we compared each group (i.e. TOL vs. control, and separately non-TOL vs. control) to 
the healthy control group using SAM. Shared genes (unidirectionally different in both TOL and 
non-TOL with reference to controls) were considered non-informative and filtered out, and thus 
unique gene lists that distinguished TOL and non-TOL from controls were developed. Finally, for 
each group of interest (TOL or non-TOL), we retained only those genes from the initial two-
group comparison that also were identified as unique genes in each comparison to control. 
Thus, the final gene list for the TOL group were those that distinguished TOL from both non-
TOL and control, and the final gene list for the non-TOL group contained those that 
distinguished non-TOL from both TOL and controls. Functional Ontology Enrichment (MetaCore 
by GeneGo) with 5% FDR filter was utilized to identify enriched canonical pathways and cellular 
process networks, and the biologic relevance of these genes was determined through 
examination of relevant literature. Finally, using these final TOL and non-TOL gene lists, a 
classifier was constructed using the leave-10%-out cross-validation method. The stability of this 
classifier was tested across configurations including a range of 20-80 total probe sets, and each 
iteration of the classifier included 10-fold cross-validation. Predictive accuracy was also 
assessed and visually presented in a receiver operating characteristic (ROC) plot. Gene set 
enrichment analysis (GSEA) was utilized to examine enrichment of the tolerance-associated 
gene set for cell lineage-specific gene expression (Hematology Expression Atlas of cell lineage-
specific genes). 
As a secondary analysis approach, a paired (matched TOL vs. non-TOL pairs) analysis 
utilizing Affymetrix MAS 5.0 comparison analysis for matched samples was performed, and 
differentially expressed genes were again mapped to pathways and process networks through 
functional ontology enrichment. We also investigated shared differentially expressed genes 
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 between our data (TOL vs. non-TOL comparison) and previously published differential gene 
expression data following solid organ transplantation (TOL vs. non-tolerant comparator), and 
mapped shared genes to enriched pathways.195,214-216 
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CHAPTER THREE: 
 
RESULTS 
 
 
 Randomized phase II study to evaluate tacrolimus in combination with sirolimus or 
methotrexate after allogeneic hematopoietic cell transplantation:   
 
 
 Patient characteristics and compliance with therapy: From September, 2008 through 
May, 2011, a total of 175 patients were assessed for eligibility. A total of 101 were excluded for 
the following: not meeting inclusion criteria (n=72), declined to participate (n=16), no insurance 
coverage for trial (n=8), and disease progression (n=5). Thus, 74 patients were randomized 1:1 
to SIR/TAC vs. MTX/TAC. None were lost to follow-up, and all were included in the reported 
analyses. Baseline characteristics were well matched (Table 1). Among 37 patients treated with 
MTX/TAC, 34 completed all doses of MTX; three received 3 doses of MTX, followed in 2 cases 
by initiation of mycophenolate mofetil as substitute prophylaxis. The final dose of MTX was not 
given for grade 4 mucositis (n=2) and liver dysfunction (n=1). Overall compliance with SIR was 
excellent: At time of study analysis for original publication, a total of 2 patients had discontinued 
SIR (both for grade I TMA, at days 77 and 150 post-HCT, respectively). Among the 17 alive and 
beyond one year of follow up at the time of that analysis, 16 were receiving SIR as planned per 
protocol. 
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Table 1:  Baseline characteristics of patients randomized to receive methotrexate or sirolimus in 
combination with tacrolimus for prevention of acute graft vs. host disease.  
 
 Methotrexate Sirolimus  
Recipient age (median, range) 48 (23-69) 49 (25-68) p = 0.36 
Gender 
Male 
Female 
 
23 
14 
 
28 
9 
 
p = 0.21 
Diagnosis 
 
ALL 
CR1 
 
AML 
CR1 
CR2 
PIF 
REL 1 
no treatment 
 
CLL 
CR 
PR 
SD 
 
CML 
CP1 
 
MDS 
CR 
HI 
SD 
Not treated 
 
MM 
CR 
VGPR 
PR 
 
MPD 
SD 
 
NHL 
CR2 
CR3 or > 
PR1 
PR2 
PIF 
REL 1 (sensitive) 
 
 
10 
10 
 
8 
5 
2 
1 
0 
0 
 
4 
2 
1 
1 
 
0 
0 
 
7 
2 
4 
1 
0 
 
2 
1 
0 
1 
 
2 
2 
 
4 
0 
1 
1 
0 
1 
1 
 
 
5 
5 
 
15 
8 
3 
2 
1 
1 
 
3 
2 
0 
1 
 
2 
2 
 
2 
0 
1 
0 
1 
 
6 
4 
1 
1 
 
0 
0 
 
4 
2 
0 
0 
1 
0 
0 
P = 0.08*
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REL 3 or > (untreated) 0 1 
 
Table 1 continued. 
 
 
CIBMTR risk category 
High 
Intermediate 
Low 
Other 
 
8 
7 
20 
2 
 
7 
7 
23 
0 
 
p = 0.52
Donor 
MRD 
MUD 
 
18 
19 
 
17 
20 
 
p = 0.82
Recipient:Donor CMV matching 
NN 
NP 
PN 
PP 
 
12 
7 
8 
10 
 
10 
1 
16 
10 
 
 
p = 0.06
Donor gender 
Female 
Male 
 
21 
16 
 
17 
20 
 
p = 0.35
Donor age (median, range) 37 (18-65) 37 (22-67) p = 0.3 
Conditioning regimen 
FluBu 
Pento/Bu 
Flu/Mel 
 
30 
5 
2 
 
26 
4 
7 
 
p = 0.22
 
 
*Diagnosis: p = 0.08, Remission status: p = 0.69 
 
ALL  = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CLL = chronic 
lymphocytic leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic 
syndrome; MM = multiple myeloma; MPD = myeloproliferative disease; NHL = non-Hodgkin 
lymphoma; CR = complete remission; PIF = primary induction failure; REL = relapse; PR = 
partial remission; SD = stable disease; CP = chronic phase; HI = hematologic improvement; 
VGPR = very good partial remission; MRD = matched sibling donor; MUD = matched unrelated 
donor; CMV = cytomegalovirus; N = negative, P = positive; Bu = busulfan; Flu = fludarabine; 
pent = pentostatin; Mel = melphalan 
 
 
 
 Engraftment and early toxicity: Time to neutrophil engraftment did not differ between 
SIR/TAC (median 16 days, range 11-22) and MTX/TAC (median 16, range 12-28), p = 0.57. 
Time to platelet engraftment was also similar for SIR/TAC (median 12, range 6-20) compared to 
MTX/TAC (median 16, range 10-33), p = 0.6. No significant differences were observed in donor 
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chimerism at any of the studied time points (day 30, 90, 360 post-HCT). Peak mucositis did not 
significantly differ for SIR/TAC vs. MTX/TAC (table 2). The cumulative incidence of hepatic VOD 
did not significantly differ (SIR/TAC 5% (95% CI 1-21%) vs. MTX/TAC 3% (95% CI 0.4-19%), 
p=0.56). VOD severity grading is presented in table 2. Notably, the observed incidence of VOD 
in this study is lower than that previously published.231 The cumulative incidence of TMA did not 
significantly differ (SIR/TAC 25% (95% CI 14-44%) vs. MTX/TAC 20% (95% CI 10-38%), 
p=0.48). TMA occurred in 9 SIR/TAC patients and 7 MTX/TAC patients, p = 0.57. Maximal TMA 
grade for SIR/TAC vs. MTX/TAC is represented in table 2.   
 
Table 2:  Summary of mucositis, thrombotic microangiopathy (TMA), and hepatic veno-occlusive 
disease (VOD) according to randomized trial study arm.  
 
Variable Levels MTX (%) SIR (%) P value 
Mucositis CTC Grade 1 3 (8.1  ) 8 (21.6 ) 0.12 
 2 9 (24.3 ) 13 (35.1 )  
 3 21 (56.8 ) 15 (40.5 )  
 4 4 (10.8 ) 1 (2.7  )  
TMA No 30 (81.1 ) 28 (75.7 ) 0.57 
 Yes 7 (18.9 ) 9 (24.3 )  
TMA grade 1 4 (10.8 ) 9 (24.3 ) 0.17 
 2 2 (5.4  ) 0 (0.0  )  
 4 1 (2.7  ) 0 (0.0  )  
 N/A 30 (81.1 ) 28 (75.7 )  
VOD No 36 (97.3 ) 35 (94.6 ) 0.56 
 Yes 1 (2.7  ) 2 (5.4  )  
VOD grade None 36 (97.3 ) 35 (94.6 ) 0.57 
 Moderate 1 (2.7  ) 1 (2.7  )  
 Severe 0 (0.0  ) 1 (2.7  )  
 Total 37 (50.0) 37 (50.0)  
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*TMA = thrombotic microangiopathy, VOD = hepatic veno-occlusive disease (sinusoidal 
obstructive syndrome), MTX = methotrexate/tacrolimus arm, SIR = sirolimus/tacrolimus arm 
  
Acute graft vs. host disease: The cumulative incidence of grade II-IV acute GVHD at 
100 days was 43% (95% CI 27-59%) in the SIR/TAC group, and 89% (95% CI 72-96%) in the 
MTX/TAC group, p < 0.001 (Figure 2). Adjusting for age > 50 vs. ≤ 50 and donor relation strata 
in a multivariable model, SIR/TAC was associated with reduced hazard for grade II-IV acute 
GVHD (HR 0.28, 95% CI 0.15-0.52, p < 0.001) compared to MTX/TAC. Significant reduction in 
grade II-IV acute GVHD was observed both for those with matched sibling donor (41% vs. 78%, 
p = 0.02) and matched unrelated donor (45% vs. 100%, p = 0.001). The cumulative incidence of 
grade III-IV acute GVHD did not significantly differ (14% vs. 11%), p = 0.71. While the observed 
incidence of grade II-IV acute GVHD in the MTX/TAC arm is higher than that reported in some 
published literature, it is consistent with that observed at our center in a previous randomized 
comparative trial.219 The inter-institution variation in the observed acute GVHD incidence is in 
large part due to how aggressively diagnostic endoscopy is pursued to assess the etiology of 
gastrointestinal symptoms.232  
Overall grade distribution significantly differed for SIR/TAC vs. MTX/TAC, based on 
reduction in overall grade II disease (Table 3). Among individual acute GHVD target organs, we 
only observed significant differences in GI stage (Table 3). When classified according to the site 
of GI involvement, SIR/TAC treated patients had reduction in both isolated upper GI (SIR n=3, 
MTX n=10) and combined upper/lower GI involvement (SIR n=5, MTX n=12), but not isolated 
lower GI involvement (SIR n=7, MTX n=7).   Utilizing time-dependent Cox modeling, we could 
not detect significant relationship between immune suppressive drug (TAC, SIR) levels and 
grade II-IV or grade III-IV acute GVHD.  
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Figure 2:  Cumulative incidence of grade II-IV acute GVHD over 100 days following HCT 
stratified according to initial GVHD prevention. 
 
 
 
*GVHD = graft vs. host disease, HCT = allogeneic hematopoietic cell transplantation, 
methotrexate = methotrexate/tacrolimus study arm, sirolimus = sirolimus/tacrolimus study arm, 
days = number of days following date of HCT 
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Table 3:  Acute and chronic GVHD characteristics of study population 
 
 
(A) Individual acute GVHD organ staging and overall acute GVHD grade 
 
 MTX SIR p value 
Skin stage    
0 15 (41%) 16 (43%) p = 0.48 
1 17 (46%) 13 (35%)  
2 3 (8%) 7 (19%)  
3 2 (5%) 1 (3%)  
4 0 (0%) 0 (0%)  
GI stage    
0 8 (22%) 22 (59%) p = 0.003
1 27 (73%) 10 (27%)  
2 1 (3%) 3 (8%)  
3 1 (3%) 1 (3%)  
4 0 (0%) 1 (3%)  
Liver stage    
0 30 (81%) 35 (95%) p = 0.32 
1 4 (11%) 1 (3%)  
2 2 (5%) 1 (3%)  
3 1 (3%) 0 (0%)  
4 0 (0%) 0 (0%)  
Overall Grade    
0 2 (5%) 11 (30%) p < 0.001
I 2 (5%) 10 (27%)  
II 29 (78%) 11 (30%)  
III 4 (11%) 4 (11%)  
IV 0 (0%) 1 (3%)  
 
*MTX/TAC = methotrexate/tacrolimus arm, SIR/TAC = sirolimus/tacrolimus arm 
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(B) Chronic GVHD scoring according to NIH Consensus Criteria: Individual organ severity 
scores and global severity score 
 
 MTX SIR p value 
Skin 
0 
1 
2 
3 
 
20 (65%) 
7 (23%) 
3 (10%) 
1 (3%) 
 
24 (73%) 
5 (15%) 
4 (12%) 
0 (0%) 
 
p = 0.62 
Mouth 
0 
1 
2 
3 
 
18 (58%) 
13 (42%) 
0 (0%) 
0 (0%) 
 
22 (67%) 
10 (30%) 
1 (3%) 
0 (0%) 
 
p = 0.42 
Eyes 
0 
1 
2 
3 
 
21 (68%) 
5 (16%) 
4 (13%) 
1 (3%) 
 
20 (61%) 
11 (33%) 
2 (6%) 
0 (0%) 
 
p = 0.27 
GI 
0 
1 
2 
3 
 
24 (77%) 
6 (19%) 
0 (0%) 
1 (3%) 
 
32 (97%) 
1 (3%) 
0 (0%) 
0 (0%) 
 
p = 0.06 
Liver 
0 
1 
2 
3 
 
17 (55%) 
5 (16%) 
8 (26%) 
1 (3%) 
 
29 (88%) 
2 (6%) 
2 (6%) 
0 (0%) 
 
p = 0.03 
Lung 
0 
1 
2 
3 
 
27 (87%) 
1 (3%) 
1 (3%) 
2 (7%) 
 
32 (97%) 
0 (0%) 
1 (3%) 
0 (0%) 
 
p = 0.34 
Joints/fascia 
0 
1 
2 
3 
 
28 (90%) 
1 (3%) 
2 (7%) 
0 (0%) 
 
31 (94%) 
1 (3%) 
1 (3%) 
0 (0%) 
 
p = 0.81 
Genital 
0 
1 
2 
3 
 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
Other 
0 
1 
2 
3 
 
30 (97%) 
0 (0%) 
0 (0%) 
1 (3%)** 
 
33 (100%)
0 (0%) 
0 (0%) 
0 (0%) 
 
p = 0.48 
Overall global score    
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0 
1 
2 
3 
11 (36%) 
1 (3%) 
11 (36%) 
8 (26%) 
17 (52%) 
10 (30%) 
5 (15%) 
1 (3%) 
p = 0.001
 
*MTX = methotrexate/tacrolimus arm, SIR = sirolimus/tacrolimus arm 
**pericardial effusion 
 
 
 
 
 
 Acute GVHD therapy: We captured comprehensive data on prednisone, 
beclomethasone and budesonide therapy for affected patients. The proportion of living patients 
on prednisone was not significantly different between groups compared weekly within 100 days 
and monthly following day 100. There was no significant difference in the proportion receiving 
systemic glucocorticoids at either 6 months (SIR/TAC 52%, MTX/TAC 59%) or 1 year (SIR/TAC 
24%, MTX/TAC 25%) following HCT (p=NS). To spare systemic glucocorticoids, patients with 
acute upper GI GVHD were treated with beclomethasone and those with acute intestinal GVHD 
with budesonide, either alone or in combination with systemic glucocorticoids.  Fewer patients in 
the SIR/TAC arm were treated with beclomethasone for manifestations of acute GVHD (p value 
for each weekly comparison for beclomethasone < 0.05 for weeks 5, 6, 9, 10 and < 0.01 for 
weeks 11-14); point-wise comparisons for budesonide were not significantly different.  Ten 
patients in SIR/TAC and 6 in MTX/TAC discontinued TAC after intentional taper in the absence 
of primary disease relapse or TAC toxicity, including TMA. The cumulative incidence of 
intentional TAC discontinuation at 30 months post-HCT did not differ across groups (SIR/TAC 
36%, MTX/TAC 30%, p = 0.16). 
 Chronic graft vs. host disease: The cumulative incidence of any grade chronic GVHD 
per NIH criteria was 53% (95% CI 29-72%) for SIR/TAC and 70% (95% CI 42-86%) for 
MTX/TAC, p = 0.68. Moderate to severe chronic GVHD was 24% (95% CI 7-47%) for SIR/TAC 
and 64% (95% CI 41-79%) for MTX/TAC, p = 0.008 (Figure 3). Cumulative incidence estimates 
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are provided at 30 months post-HCT. Adjusting for age/donor strata, moderate to severe chronic 
GVHD was significantly reduced among SIR/TAC patients (HR 0.27, 95% CI 0.1-0.72, p = 
0.009).The predominant sites of organ involvement were skin, mouth, eye, and liver, 
recapitulating previously published estimates.128 Maximum grade of chronic GVHD significantly 
differed for SIR/TAC vs. MTX/TAC (Table 3). Chronic GVHD therapy was not mandated by this 
protocol.  
 
 
(A) 
 
 
 
Figure 3:  Cumulative incidence of any grade chronic GVHD and moderate to severe chronic 
GVHD according to NIH criteria 
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(B) 
 
 
 
 
Figure 3:  Cumulative incidence of any grade chronic GVHD and moderate to severe chronic 
GVHD according to NIH criteria 
 
*GVHD = graft vs. host disease, NIH criteria = NIH Consensus Conference chronic GVHD 
diagnosis and severity scoring criteria,127 methotrexate = methotrexate/tacrolimus study arm, 
sirolimus = sirolimus/tacrolimus study arm, months = number of months following date of HCT 
 
 
 Overall survival, non-relapse mortality, and disease relapse: Median follow-up for 
surviving patients at the time of study analysis was 20 months (range 4-32) for SIR/TAC, and 17 
months (range 4-32) for MTX/TAC. Overall survival did not significantly differ between groups. 
Two year OS was 61% (95% CI 41-77%) for SIR/TAC and 69% (95% CI 48-83%) for MTX/TAC, 
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p = 0.66.  We did not observe significant difference in primary disease relapse: The 2-year 
cumulative incidence of relapse was 18% for SIR/TAC and 31% for MTX/TAC, p = 0.09. 
Adjusting for age/donor strata, the hazard for relapse was not significantly different between the 
two arms (HR 0.41, 95% CI 0.15-1.14, p = 0.09). Relapse of malignancy was the primary cause 
of death for 2 patients in the SIR/TAC arm, and 7 patients in the MTX/TAC arm.  The two year 
incidence of non-relapse mortality (NRM) was 28% for SIR/TAC and 8% for MTX/TAC, p = 
0.025. Adjusting for age/donor strata, the hazard for NRM among SIR/TAC patients (reference 
MTX/TAC) was increased (HR 4.95, 95% CI 1.1-22.3, p = 0.04). Non-relapse causes of death 
occurred in 8 patients in the SIR/TAC arm (septicemia in 2, hepatic VOD, multi-organ failure, 
acute GVHD, chronic GVHD and hepatic failure, influenza and respiratory failure, and RSV 
pneumonia in one each), and 2 patients in the MTX/TAC arm (alveolar hemorrhage, and 
unknown).   
Analysis of Patient-reported quality of life (QOL):  The Functional Assessment of 
Cancer Therapy – Bone Marrow Transplant (FACT-BMT) was utilized to assess QOL at days 
30, 90, 180, 270, and 360 after HCT.223  The FACT-BMT is a 47-item measure with reliability 
and validity in HCT patients.223,233  It yields a total score as well as subscales assessing physical 
well-being (PWB), functional well-being (FWB), social/family well-being (SWB), emotional well-
being (EWB), and BMT-specific concerns (BMTS).  A trial outcome index (TOI) is calculated by 
summing the PWB, FWB, and BMTS subscales.  TOI was selected as the QOL outcome of 
interest due to its sensitivity to GVHD.234,235  Higher scores indicate better QOL.  As in previous 
research,236,237 a difference of 5–9 points on the TOI was considered clinically meaningful. 
Because groups did not display equivalent QOL at baseline,238 we examined the trajectory of 
QOL over the five post-HCT assessment points (i.e., days 30, 90, 180, 270, and 360), 
controlling for pre-HCT QOL.  Thus, the analysis examines the effect of study arm on post-HCT 
change in QOL independent of baseline QOL. Three participants did not provide enough QOL 
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data to calculate trajectories, resulting in 71 participants who contributed data to the current 
analyses.  BMT-TOI scores were normally distributed. Results indicated that TOI increased 
significantly over time in both study arms (p<.01).  Nevertheless, study arm significantly 
predicted TOI at day 360 such that scores in the SIR/TAC group were a mean of 7.17 points 
lower than the MTX/TAC group (p=.03).  There was also a significant effect of study arm over 
time indicating that the SIR/TAC arm showed smaller improvements in TOI than the MTX/TAC 
arm (p=.02). Multivariate analyses accounting for effects of acute and chronic GVHD and 
anemia demonstrated that the SIR/TAC group reported TOI scores 9.54 points lower at day 360 
(p<.01) and demonstrated less improvement in TOI over time when controlling for potential 
clinical confounders (p<.01).  These data indicate that prolonged administration of SIR after 
HCT is associated with inferior QOL through one year post-HCT, despite reduction in significant 
chronic GVHD.239 This finding highlights a disparity between clinician and patient perception of 
benefit, and suggests the importance of inclusion of patient-reported outcomes in GVHD 
prevention trials. 
 Regulatory T cell reconstitution and suppressive function: Samples were obtained 
at the specified time points to characterize Treg in peripheral blood. There was significantly 
greater proportion of Treg/total CD4+ cells at day 30 and day 90 in SIR/TAC patients (Figure 4). 
There were increased absolute numbers of Treg and decreased absolute numbers of non-Treg 
CD4+ cells at these time points (figures 5 and 6). In a subset of patients from SIR/TAC (n=4) 
and MTX/TAC (n=5), functional assays were performed on samples obtained at day 90 (SIR 
n=2, MTX n=1), day 180 (SIR n=2, MTX n=3) and day 360 (MTX n=1).  All patients were on 
systemic immune suppression at the time these samples were obtained: Of SIR/TAC patients, 
this included SIR (n=4), TAC (n=3), and prednisone (n=2), ranging from 0.17 – 1mg/kg/day. For 
MTX/TAC patients, this included TAC (n=5), SIR (n=1), and prednisone (n=2), ranging 0.1 – 
0.83mg/kg/day.  For escalating ratio of sorted Treg to T responder cells, we observed increasing 
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% suppression achieved. While these Treg were functional, we did not observe significant 
differences in suppressive function between the SIR/TAC and MTX/TAC treated patients (figure 
7). 
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      (n=73)       (n=74)       (n=73)      (n=66)       (n=47)       (n=37) 
 
 
Figure 4:  Reconstitution of Treg (Treg/total CD4+ cells) following transplantation according to   
GVHD prophylaxis regimen 
 
* Day 30 (p < 0.0001), day 90 (p = 0.0009), day 180 (p = 0.07), otherwise, p = not significant. 
(box and whisker plot: box margins = interquartile range, line = median value, whiskers = 95% 
confidence interval, dots = outliers).  Treg = regulatory T cells (defined by cell surface 
phenotype of CD4+CD25+CD127-),  total CD4+ cells = total number of CD4 T cells (defined by 
cell surface phenotype of CD4+), HCT = allogeneic hematopoietic cell transplantation, 
methotrexate = methotrexate/tacrolimus study arm, sirolimus = sirolimus/tacrolimus study arm, 
days = number of days following date of HCT 
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Figure 5:  Reconstitution of Treg (absolute number of Treg) following transplantation according 
to GVHD prophylaxis regimen 
 
* P value = not significant for each comparison. (box and whisker plot: box margins = 
interquartile range, line = median value, whiskers = 95% confidence interval, dots = outliers).   
MTX = methotrexate/tacrolimus study arm, SIR = sirolimus/tacrolimus study arm; Treg = 
absolute number of regulatory T cells/uL (Treg phenotype = CD4+CD25+CD127-), days = 
number of days following date of HCT. 
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Figure 6:  Reconstitution of non-Treg (absolute number of non-Treg CD4+) following 
transplantation according to GVHD prophylaxis regimen 
 
* P value = not significant for each comparison. (box and whisker plot: box margins = 
interquartile range, line = median value, whiskers = 95% confidence interval, dots = outliers).   
MTX = methotrexate/tacrolimus study arm, SIR = sirolimus/tacrolimus study arm, non-Treg = 
absolute number of CD4+ cells minus absolute number of CD4+CD25+CD127+ Treg, days = 
number of days following date of HCT. 
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(C) 
 
 
 
Figure 7:  Suppressive function of Treg according to GVHD prophylaxis regimen 
 
 
 
*(A) Sorted Treg were tested at different ratios to self CD4+CD25- T cell effectors in the 
presence of anti-CD3/CD28 beads. Results are shown as average CPM of triplicate measured 
by the incorporation of 3H-thymidine in co-cultures at day 5 after subtracting the CPM of 
background wells without Treg (p = not significant for comparisons).  (B) Absolute number of 
Treg per mL for SIR or MTX groups as determined by flow cytometry. (C) Suppressive units for 
SIR or MTX groups:  IC25 of Treg was calculated for suppression of 1 x 104 T effectors.  One 
suppressive unit represents the measure of absolute number of Tregs per mL of blood divided 
by number Treg capable of suppressing 25% T effectors. SIR = sirolimus/tacrolimus study arm, 
MTX = methotrexate/tacrolimus study arm, Treg = sorted CD4+CD25+CD127- cells, T effectors 
= self CD4+CD25- T responder cells 
 
 
 
 Tissue-infiltrating Th1, Th17, and Treg in GVHD target organs following human allogeneic 
hematopoietic cell transplantation: 
 
 
 Included samples: A total of 48 patients (SIR: n=25, MTX: n=23) contributed 110 
GVHD biopsies to the analysis. Acute GVHD organ biopsy sites, as well as clinical and 
pathologic grade are represented in table 4, and lymphocyte numbers per TMA core are 
presented in table 5. Time from GVHD biopsy to topical (p=0.17) or systemic glucocorticoid 
(p=0.55) therapy did not differ between SIR and MTX-treated patients. RORy and CD4 co-
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registration analysis demonstrated that the majority of RORy+ cells were dual positive for CD4 
(median 98%, range 89-99.6%).  
 
Table 4:  GVHD organ involvement, pathologic, and clinical grade of GVHD tissue biopsies 
according to GVHD prevention study arm. 
 
  SIR (%) MTX (%) Total (%) p value 
Pathologic grade 1 23 (38.3) 15 (31.9) 38 (35.5) NS 
  2 26 (43.3) 21 (44.7) 47 (43.9)   
  3 11 (18.3) 9 (19.1) 20 (19.6)   
 4 0 (0) 2 (4.3) 2 (1.9)  
  Total 60 (56.1) 47 (43.9) 107 (100)   
Biopsy organ site Gastric antrum 15 (23.8) 12 (25.5) 27 (24.5) NS 
  Duodenum 18 (28.6) 12 (25.5) 30 (27.3)   
  Rectum 19 (30.2) 15 (31.9) 34 (30.9)   
 Liver 1 (1.6) 2 (4.3) 3 (2.7)  
  Skin 10 (15.9) 6 (12.8) 16 (14.5)   
  Total 63 (57.3) 47 (42.7) 110 (100.0)   
Clinical grade 1 18 (28.6 ) 0 (0) 18 (16.4) <.0001 
  2 31 (49.2) 44 (93.6) 75 (68.2)   
  3 11 (17.5) 3 (6.4) 14 (12.7)   
  4 3 (4.8) 0 (0.0) 3 (2.7)   
  Total 63 (57.3) 47 (42.7) 110 (100.0)   
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*SIR=rapamycin/tacrolimus GVHD prophylaxis group, MTX=methotrexate/tacrolimus GVHD 
prophylaxis group, NS=not significant 
 
Table 5:  Tissue-resident lymphocyte subsets according to GVHD prophylaxis group 
 SIR  
Median (range) 
MTX  
Median (range)
p value
Total CD4 315 (4-3229) 246 (9-2102) NS 
Th1 48 (7-344) 40 (4-504) NS 
Th17 4 (1-110) 9.5 (2-92) 0.01 
Treg 5 (0-132) 6.5 (0-113) NS 
 
*SIR = sirolimus/tacrolimus GVHD prophylaxis group, MTX = methotrexate/tacrolimus GVHD 
prophylaxis group, NS=not significant 
 
 
Association between tissue-resident CD4 subsets and GVHD severity and 
response to therapy: Th17 increased (median values - grade 1: 5, grade 2: 8, grade 3/4: 20.5) 
with pathologic grade (figure 8). Two-way ANOVA adjusted for GVHD organ site demonstrated 
that Th17 (p=0.033) and Th17/CD4 (p=0.021) were significantly associated with pathologic 
grade. No other subsets were associated with pathologic grade. We found no association of 
lymphocyte subsets with overall clinical GVHD grade. In subset analysis of GI stage, however, 
two-way ANOVA adjusted for site of GI organ involvement demonstrated that Th17/CD4 
increased with greater GI organ stage (p=0.004). In comparison to MTX/TAC, SIR/TAC-treated 
patients had significantly lower Th17 cells (table 5, figure 9). Adjusted for clinical and pathologic 
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grade, SIR/TAC remained significantly associated with lower Th17 (p=0.04). Other lymphocyte 
subsets did not differ between SIR/TAC and MTX/TAC groups. Refractoriness to standard 
GVHD therapy (≥ 1mg/kg/day prednisone or equivalent) was defined as lack of complete or 
partial response by 28 days of therapy, as this is a validated predictor of subsequent non-
relapse mortality.30 Those with refractory acute GVHD had significantly increased (refractory 
median 27 vs. responsive median 5) number of Th17 present in affected tissues (figure 10). 
Logistic regression analysis demonstrated that tissue Th17 were significantly associated with 
refractoriness (OR 6.6, 95% CI 1.6-27, p=0.008), and clinical grade was also associated with 
refractoriness (grade 3-4 vs. 1: OR 4.4, 95% CI 0.7-25.7, p=0.019). Th17 was also significantly 
associated with refractoriness in a sub-group analysis limited to GI cases. 
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Figure 8:  Tissue-resident Th17 cells according to GVHD pathologic grade 
 
*(A) shows increased ROR gamma positive lymphocytes in a rectal biopsy from a patient with 
pathologic grade 3 GVHD. (B) shows fewer ROR gamma positive lymphocytes in a rectal biopsy 
from a patient with pathologic grade 1 GVHD.  [ROR gamma, x400].  (C) Scatter plot shows 
absolute number of tissue-resident Th17 by pathologic GVHD grade .  Line depicts median. 
NS=not significant, *P < 0.05. 
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Figure 9:  Target-organ Th17 cells according to GVHD prophylaxis regimen 
 
*(A) shows ROR gamma positive lymphocytes in the duodenal lamina propria of a patient who 
received SIR/TAC.  (B) shows increased ROR gamma positive lymphocytes in the duodenal 
lamina propria from a patient who received MTX/TAC.  Both patients were diagnosed with 
pathologic grade 2 GVHD.  [ROR gamma, x400].  (C) Scatter plot shows absolute number of 
tissue-resident Th17 by use of rapamycin (sirolimus) or methotrexate GVHD prophylaxis.  Line 
depicts median. *P < 0.05. 
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Figure 10:  Tissue-resident Th17 cells according to GVHD therapy response 
 
*(A) Increased ROR gamma positive lymphocytes in the lamina propria from rectal biopsy. 
Panel A patient was diagnosed with pathologic grade 3 GVHD and was refractory to steroid 
therapy.  (B) Shows fewer ROR gamma positive lymphocytes in the lamina propria on rectal 
A  B
C
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biopsy.  The panel B patient was diagnosed with pathologic grade 2 GVHD in the rectum and 
was responsive to steroid therapy. [ROR gamma, x400].  (C) Scatter plot shows absolute 
number of tissue-resident Th17 by response to corticosteroid therapy.  Line depicts median. **P 
< 0.01. 
 
  
 
Tolerance associated gene expression following allogeneic hematopoietic cell 
transplantation: 
 
 
 Patient characteristics: A total of 15 tolerant patients after HCT were identified and had 
sample collection. Two additional tolerant cases were identified, but were not able to participate 
in the study. A total of 17 non-tolerant comparators were selected based on age, time from 
HCT, and other clinical transplantation characteristics, and had samples collected. 
Demographic, transplantation, and GVHD characteristics of the included patients are detailed in 
table 6. Finally, a total of 10 healthy volunteer control subjects were recruited. These were 
without acute or chronic illness, and were not on any medications. Median age of controls was 
32.5 (range 27-59) years, and included 7 females and 3 males. The TOL and non-TOL patients 
did not significantly differ according to demographic, disease, or transplantation characteristics 
(table 6). These were adult patients with hematologic malignancies and disorders predominantly 
treated with myeloablative chemotherapy-based conditioning. The majority received peripheral 
blood stem cells from either matched sibling or matched unrelated doors. Initial GVHD 
prophylaxis was a calcineurin inhibitor together with either methotrexate or mycophenolate 
mofetil, and acute GVHD severity and treatment did not differ between groups.  
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Table 6:  Comparison of patient, transplantation, and GVHD variables across tolerant and non-
tolerant groups in analysis of differential gene expression associated with immune tolerance. 
 
Variable Tolerant Non-Tolerant p value  
Median age 50 49 0.79 
Donor age 38 52 0.11 
Condition 
AA 
ALL 
AML 
CML 
FL 
HD 
IMF 
MCL 
MCL, MDS 
MDS 
MM 
MPD 
 
1 
2 
3 
0 
2 
0 
0 
2 
1 
3 
0 
1 
 
0 
3 
7 
1 
2 
1 
1 
0 
0 
1 
1 
0 
 
0.39 
Stem cell source 
PBSC 
BM 
 
15 
0 
 
16 
1 
 
0.34 
Donor relation 
MMUD 
MRD 
MUD 
 
1 
10 
4 
 
0 
11 
6 
 
0.51 
Donor:recipient gender matching 
Female/female 
Female/male 
Male/female 
Male/male 
 
3 
2 
2 
8 
 
6 
5 
1 
5 
 
 
0.36 
HLA matching 
Matched  
mismatched 
 
14 
1 
 
17 
0 
 
0.28 
CMV serostatus recipient:donor 
Neg/neg 
Neg/pos 
Pos/neg 
Pos/pos 
 
4 
1 
5 
5 
 
10 
2 
1 
4 
 
 
0.13 
Conditioning  
Bu/Cy 
Bu/Flu 
Bu/Flu/ATG 
Bu/Flu/R 
Cy/ATG 
Cy/BCNU/VP16 
Cy/TBI 
Flu/Cy/R 
Pento/Bu/R 
 
1 
8 
1 
1 
1 
1 
1 
1 
1 
 
2 
14 
0 
0 
0 
0 
1 
0 
0 
 
0.35 
aGVHD prophylaxis 
agent 1 
CSA 
 
 
1 
 
 
2 
 
 
0.51 
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CSA/TAC 
TAC 
1 
13 
0 
15 
aGVHD prophylaxis  
agent 2 
MMF 
MTX 
 
 
6 
9 
 
 
6 
11 
 
 
0.78 
Max grade aGVHD 
None 
I 
II 
III 
IV 
 
4 
4 
5 
1 
1 
 
2 
1 
11 
2 
1 
 
0.29 
aGVHD treatment agent 1 
none 
MMF 
Pred < 1mg/kg 
Pred 1 mg/kg 
Pred 2 mg/kg 
 
7 
0 
1 
4 
3 
 
7 
1 
0 
9 
0 
 
 
0.15 
aGVHD treatment agent 2 
none 
MMF 
Rapa 
 
10 
2 
3 
 
13 
4 
0 
 
 
0.03 
Max grade cGVHD 
None 
Mild 
Moderate 
Severe 
 
9 
6 
0 
0 
 
0 
5 
8 
4 
 
0.0001 
cGVHD treatment agent 1 
Prednisone 
ECP 
MMF 
TAC 
Rapa 
none 
 
1 
0 
0 
0 
0 
14 
 
3 
1 
3 
1 
1 
8 
 
 
0.13 
cGVHD treatment agent 2 
MMF 
MTX 
Rapa 
TAC 
none 
 
0 
0 
0 
0 
15 
 
2 
1 
3 
2 
9 
 
 
0.001 
cGVHD treatment agent 3 
CSA 
Prednisone 
Rapa 
none 
 
0 
0 
0 
15 
 
2 
1 
1 
13 
 
 
< 0.0001
 
*Categorical data compared with Fisher’s exact test or Chi-square, continuous data utilized wilcoxon rank 
sum test 
 
* AA – aplastic anemia; ALL – acute lymphoblastic leukemia; AML – acute myelogenous leukemia; CML – 
chronic myelogenous leukemia; FL – follicular lymphoma; HD – Hodgkin lymphoma; IMF – idiopathic 
myelofibrosis; MCL – mantle cell lymphoma; MDS – myelodysplastic syndrome; MM – multiple myeloma; 
MPD – myeloproliferative neoplasm; PBSC – peripheral blood stem cells; BM – bone marrow harvested 
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stem cells; MMUD – mismatched unrelated donor; MRD – matched sibling donor; MUD – matched 
unrelated donor; HLA – human leukocyte antigen; CMV – cytomegalovirus; neg – negative; pos – 
positive; Bu – busulfan; Cy – cyclophosphamide; Flu – fludarabine; ATG – anti-thymocyte globulin; R – 
rituximab; BCNU – carmustine; VP16 – etoposide; TBI – total body irradiation; pento – pentostatin; CSA – 
cyclosporine; TAC – tacrolimus; MMF – mycophenolate mofetil; MTX – methotrexate; aGVHD – acute 
graft vs. host disease; pred – prednisone; rapa – rapamycin (sirolimus); ECP – extra-corporeal 
photopheresis; cGVHD – chronic graft vs. host disease 
 
 
The TOL and non-TOL groups did significantly differ in their history of chronic GVHD, as 
the non-TOL patients had greater NIH Consensus global severity of chronic GVHD and greater 
extent of therapy delivered for chronic GVHD: Among the TOL patients, 9 had no history of 
chronic GVHD, and 6 had a prior maximum mild chronic GVHD. Of these, only one required the 
addition of any systemic IS for chronic GVHD therapy. Among the TOL patients with any history 
of chronic GVHD, this was completely resolved at a median of 25.3 months (range 17.6 – 39.7) 
prior to the study sample acquisition. In contrast, the maximum global severity of chronic GVHD 
among the non-TOL patients was 1 (n=5), 2 (n=8), or 3 (n=4). Chronic GVHD organ 
involvement included skin (n=11), eye (n=6), mouth (n=6), GI (n=5), liver (n=8), lung (n=2), and 
fascia/joints (n=1). Therapy delivered included prednisone and additional systemic immune 
suppressive therapies, and none had discontinued all IS by time of study sample acquisition. 
The median time from HCT to study sample acquisition (TOL 38.5 vs. non-TOL 39.5 months) 
did not differ between groups, p=0.97. The median time from complete IS discontinuation to 
study sample acquisition among TOL patients was 19.15 (range 7.1 – 68) months.  
Immune cell subsets: Immune cell subsets were identified through evaluation of cell 
surface markers (table 7). There was a suggestion toward increased total CD8+ T cells, and 
specifically CD8 αβ T cells in the TOL group. However, based on our pre-specified significance 
level of 0.01 in the setting of multiple comparisons, we did not observe significant differences in 
any of the studied immune subsets between TOL and non-TOL groups. Accordingly, we did not 
incorporate cell subset composition into subsequent gene expression analyses.  
  
Table 7: 
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Two-group (TOL vs. non-TOL) analysis: In the initial two-group comparison, SAM 
identified 231 probe sets over- and 412 under-expressed in the TOL vs. non-TOL group. 
Enriched process networks included those related to NK cells (NK cell cytotoxicity), 
phagocytosis and antigen presentation (phagocytosis, phagosome in antigen presentation), B 
cell signaling (BCR pathway), and lymphocyte differentiation and signaling (T helper cell 
differentiation, TCR signaling, protein C signaling, anti-apoptosis mediated via MAPK and 
JAK/STAT, lymphocyte proliferation, JAK-STAT pathway, and Th17-derived cytokines) (figure 
11). The secondary matched paired analysis identified 255 probe sets over- and 150 under-
expressed in the TOL vs. non-TOL groups. Enriched process networks included TCR signaling 
(p = 1.1E-05), T helper cell differentiation (p = 0.00086), BCR pathway signaling (p = 0.0029), 
and NK cell cytotoxicity (p = 0.009). Differentially expressed genes in our analysis were 
compared with those identified in published comparisons of tolerant vs. non-tolerant 
comparators in liver and kidney transplantation, and these were mapped to enriched cellular 
process networks (figure 12).  
 
 
cellular process networks p value ratio 
(involved)  /  (total) 
Inflammation_NK cell cytotoxicity 1.553E-09 22 164 
Immune response_Antigen presentation 2.233E-07 21 197 
Inflammation_Neutrophil activation 5.064E-06 20 219 
Reproduction_Feeding and Neurohormone signaling 1.082E-05 19 211 
Immune response_Phagocytosis 2.234E-05 19 222 
Chemotaxis 4.077E-05 14 137 
Cell adhesion_Amyloid proteins 4.853E-05 17 195 
Cell adhesion_Platelet aggregation 1.924E-04 14 158 
Immune response_T helper cell differentiation 2.050E-04 13 140 
Inflammation_Interferon signaling 3.337E-04 11 110 
Cell adhesion_Leucocyte chemotaxis 8.981E-04 15 205 
Inflammation_Histamine signaling 1.264E-03 15 212 
Proliferation_Lymphocyte proliferation 3.036E-03 14 209 
Inflammation_IL-2 signaling 3.175E-03 9 104 
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Signal Transduction_Cholecystokinin signaling 3.610E-03 9 106 
Autophagy_Autophagy 5.004E-03 6 55 
Inflammation_IgE signaling 6.168E-03 10 136 
Inflammation_Jak-STAT Pathway 8.599E-03 12 188 
Proteolysis_Proteolysis in cell cycle and apoptosis 1.048E-02 9 125 
Immune response_Phagosome in antigen presentation 1.122E-02 14 243 
Immune response_TCR signaling 1.248E-02 11 174 
Inflammation_Protein C signaling 1.318E-02 8 108 
Apoptosis_Anti-Apoptosis mediated by external signals via 
MAPK and JAK/STAT 
1.517E-02 11 179 
Development_Neurogenesis_Axonal guidance 1.655E-02 13 230 
Blood coagulation 1.937E-02 7 94 
Cell adhesion_Cell junctions 1.960E-02 10 162 
Inflammation_Amphoterin signaling 2.145E-02 8 118 
Proliferation_Positive regulation cell proliferation 2.753E-02 12 221 
Development_Regulation of angiogenesis 2.926E-02 12 223 
Cardiac development_Wnt_beta-catenin, Notch, VEGF, IP3 and 
integrin signaling 
3.068E-02 9 150 
Signal transduction_WNT signaling 3.355E-02 10 177 
Development_Blood  vessel morphogenesis 3.390E-02 12 228 
Immune response_IL-5 signalling 3.825E-02 4 44 
Cell adhesion_Glycoconjugates 4.654E-02 9 162 
 
 
 
 
Figure 11:  Enriched cellular process networks for study of differential gene expression across 
tolerant and non-tolerant cases.  
 
 
* Cellular process networks are ranked in descending order based on p value for magnitude of 
enrichment of experimental data to annotated networks using MetaCore by GeneGo software 
(limited to those with p < 0.05). Ratio of involved/total genes indicates the enrichment (number 
of genes involved per total number of genes annotated for each indicated process network) of 
differential genes for the indicated cellular process network.  
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cellular process networks  p value 
(solid organ) / (HCT) 
minimum  
(p value) 
ratio 
(involved) / (total) 
Inflammation_NK cell cytotoxicity 6.239e-3 / 2.916e-9 2.916E-09 30 164 
Chemotaxis 8.023e-8 / 5.866e-5 8.023E-08 29 137 
Inflammation_Neutrophil activation 5.617e-3 / 1.389e-7 1.389E-07 33 219 
Cell adhesion_Amyloid proteins 2.722e-1 / 3.292e-7 3.292E-07 26 195 
Immune response_Phagocytosis 1.065e-3 / 7.266e-7 7.266E-07 36 222 
Immune response_Phagosome in antigen 
presentation 
1.905e-6 / 9.972e-4 1.905E-06 37 243 
Inflammation_IL-4 signaling 3.185e-6 / 2.647e-1 3.185E-06 18 115 
Immune response_Antigen presentation 1.967e-3 / 6.449e-6 6.449E-06 31 197 
Reproduction_Feeding and Neurohormone 
signaling 
4.162e-2 / 1.739e-5 1.739E-05 27 211 
Immune response_BCR pathway 3.083e-5 / 2.211e-2 3.083E-05 25 137 
Cell adhesion_Leucocyte chemotaxis 1.140e-3 / 4.091e-5 4.091E-05 30 205 
Cell adhesion_Platelet-endothelium-
leucocyte interactions 
5.144e-5 / 1.536e-1 5.144E-05 25 174 
Development_Neurogenesis_Axonal 
guidance 
3.878e-3 / 5.783e-5 5.783E-05 34 230 
Development_EMT_Regulation of 
epithelial-to-mesenchymal transition 
6.085e-5 / 7.855e-2 6.085E-05 31 226 
Inflammation_Histamine signaling 4.106e-3 / 6.375e-5 6.375E-05 30 212 
Cell adhesion_Platelet aggregation 2.115e-1 / 7.520e-5 7.520E-05 21 158 
Inflammation_Amphoterin signaling 1.004e-2 / 2.085e-4 2.085E-04 20 118 
Inflammation_TREM1 signaling 2.183e-4 / 7.069e-2 2.183E-04 21 145 
Immune response_T helper cell 
differentiation 
6.623e-2 / 2.839e-4 2.839E-04 19 140 
Cell adhesion_Cell junctions 3.689e-1 / 3.518e-4 3.518E-04 20 162 
Inflammation_Protein C signaling 1.950e-1 / 3.778e-4 3.778E-04 14 108 
Inflammation_Interferon signaling 5.743e-4 / 1.677e-3 5.743E-04 19 110 
Cell cycle_G2-M 1.203e-3 / 9.983e-1 1.203E-03 18 206 
Signal Transduction_Cholecystokinin 
signaling 
8.818e-2 / 1.264e-3 1.264E-03 14 106 
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Signal Transduction_TGF-beta, GDF and 
Activin signaling 
1.291e-3 / 3.185e-1 1.291E-03 18 154 
Cell adhesion_Integrin-mediated cell-matrix 
adhesion 
1.822e-3 / 1.957e-1 1.822E-03 25 214 
Cell adhesion_Glycoconjugates 2.092e-3 / 3.444e-3 2.092E-03 24 162 
Proliferation_Positive regulation cell 
proliferation 
1.753e-1 / 2.640e-3 2.640E-03 23 221 
Apoptosis_Anti-Apoptosis mediated by 
external signals via MAPK and JAK/STAT 
5.893e-2 / 2.808e-3 2.808E-03 23 179 
Development_Regulation of angiogenesis 2.819e-3 / 1.683e-2 2.819E-03 27 223 
Proteolysis_ECM remodeling 3.399e-3 / 2.528e-1 3.399E-03 12 85 
Development_Blood  vessel 
morphogenesis 
3.546e-3 / 4.204e-2 3.546E-03 26 228 
Inflammation_IL-2 signaling 1.732e-1 / 3.956e-3 3.956E-03 13 104 
Proliferation_Lymphocyte proliferation 3.424e-1 / 4.093e-3 4.093E-03 20 209 
Signal transduction_ERBB-family signaling 5.399e-3 / 1.889e-1 5.399E-03 11 75 
Autophagy_Autophagy 1.379e-2 / 5.872e-3 5.872E-03 9 55 
Immune response_TCR signaling 2.335e-2 / 6.104e-3 6.104E-03 22 174 
Cytoskeleton_Regulation of cytoskeleton 
rearrangement 
6.295e-3 / 1.003e-1 6.295E-03 22 183 
Apoptosis_Apoptotic mitochondria 6.331e-3 / 9.061e-1 6.331E-03 9 77 
Proliferation_Negative regulation of cell 
proliferation 
6.599e-3 / 1.899e-1 6.599E-03 20 184 
Cytoskeleton_Actin filaments 1.040e-1 / 6.673e-3 6.673E-03 20 176 
Inflammation_Kallikrein-kinin system 6.915e-3 / 1.937e-1 6.915E-03 21 185 
Inflammation_IgE signaling 1.184e-1 / 7.734e-3 7.734E-03 17 136 
Immune response_Th17-derived cytokines 6.344e-2 / 9.123e-3 9.123E-03 15 98 
Development_Cartilage development 9.340e-3 / 3.195e-1 9.340E-03 9 66 
Inflammation_Jak-STAT Pathway 3.921e-2 / 1.103e-2 1.103E-02 21 188 
Proteolysis_Proteolysis in cell cycle and 
apoptosis 
4.732e-1 / 1.283e-2 1.283E-02 13 125 
Signal transduction_Leptin signaling 1.411e-2 / 2.143e-1 1.411E-02 13 106 
Signal transduction_WNT signaling 1.899e-1 / 1.759e-2 1.759E-02 19 177 
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Apoptosis_Anti-apoptosis mediated by 
external signals via NF-kB 
1.860e-2 / 1.173e-1 1.860E-02 14 111 
 
 
Figure 12:  Enriched cellular process networks shared between experimental data and 
published tolerance-associated gene expression data in solid organ transplantation 
 
*Cellular process networks are ranked in descending order based on p value for magnitude of 
enrichment (minimum p value for either solid organ or HCT data) to annotated networks using 
MetaCore by GeneGo software for each process network. Ratio of involved/total genes 
indicates the enrichment (number of genes involved per total number of genes annotated for 
each indicated process network) of differential genes for the indicated cellular process network. 
Solid organ = published solid organ transplant data,195,214-216 and HCT = HCT experimental data.  
 
 
Three group (TOL vs. non-TOL vs. control) analysis: SAM identified 655 probe sets 
differentially expressed between TOL and non-TOL groups. The TOL vs. control analysis 
identified 5,687 probe sets, of which 2,273 were unique after filtering out non-informative shared 
probe sets (those represented in both TOL vs. control and non-TOL vs. control lists and 
unidirectionally different from control). The non-TOL vs. control analysis identified 4,788 probe 
sets, of which 1,376 were unique. The final TOL list contained 281 probe sets, which were 
differentially expressed in the TOL group vs. both the non-TOL and control groups. The final 
non-TOL list contained 122 probe sets which were differentially expressed compared to both 
TOL and control groups.  
Differentially expressed probe sets in the TOL and non-TOL groups were enriched for 
immune response genes focused in the innate immune response, NK cytotoxicity, lymphocyte 
signaling and regulation, apoptosis and cell cycle control. The direction and magnitude of 
differences with respect to each comparison group is represented in figure 13 and figure 14 for 
selected genes; from the total 281 TOL and 122 non-TOL probe sets, these genes were 
selected for presentation based on their association with top-scored cellular process networks, 
> 2-fold change vs. comparator groups, and relevance to established mechanisms of immune 
tolerance. 
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gene family, member B; CARD16 - caspase recruitment domain family, member 16; SOD2 - superoxide 
dismutase 2, mitochondrial. 
 
Classifier construction and cross-validation: The leave-k-out cross-validation method 
was utilized to train a classifier for the phenotypic groups (TOL vs. non-TOL) based on the 
observed differential gene expression. For each of 10 rounds of cross-validation, 10% of the 
total sample was left out for testing the classifier. An accurate classifier (90.6% accuracy, 
correctly classifying 14/15 TOL cases and 15/17 non-TOL cases) was developed only utilizing 
20 probe sets, and classifier accuracy was stable (ranging from 87.5 to 90.6%) across the range 
of included (20-80 total) probe sets.  The highest ranked (selected for classifier development 9-
10 times out of 10 total rounds of cross-validation) probe sets and corresponding genes from 
the 20-probeset classifier are listed in table 8. 
Table 8:  Top probe sets and corresponding genes selected in classifier construction and leave-
10%-out cross-validation. 
 
Number of times 
selected 
Probe set ID Gene symbol Gene name 
10 235230_at 
 
PLCXD2 
 
phosphatidylinositol-specific 
phospholipase C, X domain 
containing 2 
10 231776_at 
 
EOMES 
 
eomesodermin 
 
10 226625_at 
 
TGFBR3 
 
transforming growth factor, beta 
receptor III 
 
10 219566_at 
 
PLEKHF1 
 
pleckstrin homology domain 
containing, family F (with FYVE 
domain) member 1 
10 214119_s_at 
 
FKBP1A 
 
FK506 binding protein 1A, 12kDa 
10 206974_at 
 
CXCR6 
 
chemokine (C-X-C motif) receptor 6 
10 206486_at 
 
LAG3 
 
lymphocyte-activation gene 3 
10 204787_at 
 
VSIG4 
 
V-set and immunoglobulin domain 
containing 4 
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10 204731_at 
 
TGFBR3 
 
transforming growth factor, beta 
receptor III 
 
10 204530_s_at 
 
TOX 
 
thymocyte selection-associated high 
mobility group box 
10 1557985_s_at 
 
CEP78 
 
centrosomal protein 78kDa 
9 218832_x_at 
 
ARRB1 
 
arrestin, beta 1 
 
The accuracy of this gene expression based classifier is further demonstrated in the following 
ROC plot of sensitivity (true positive rate) vs. 1-specificity (false positive rate), indicating an AUC 
of 0.97 with 95% CI of 0.82-0.97 (figure 15). 
 
 
Figure 15:  Receiver operating characteristic (ROC) curve demonstrating accuracy of developed 
gene classifier for tolerant phenotype. 
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Cell subtype enrichment analysis: The identified final unique gene sets for the TOL (n 
= 281) and non-TOL (n = 122) groups were studied for enrichment for lineage-specific gene sets 
previously identified through an analysis of sorted peripheral blood populations defined as 
follows: CD4+ Th lymphocytes, CD8+ Tc lymphocytes, CD14+ monocytes, CD19+ B 
lymphocytes, CD56+ NK cells, and CD66+ granulocytes. Appealing to this Hematology 
Expression Atlas of cell lineage-specific genes, we performed gene set enrichment analysis 
(GSEA Analysis, Broad Institute). The analysis demonstrated a high degree of enrichment for 
NK cell lineage-specific genes (Enrichment Score (ES) 0.84, p value < 0.0001, false discovery 
rate (FDR) < 0.0001) for tolerance-associated genes represented in our experimental data 
(figure 16). No significant enrichment was detected through this method for the other studied 
cell lineages (CD4+ and CD8+ T cells, monocytes, B cells, or granulocytes) for our tolerance 
genes. 
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over-expressed in the TOL group; this molecule is involved in immune regulation, negatively 
regulates B cell receptor signaling,241 and may distinguish a distinct subset of Treg.242 Major 
components of the toll-like receptor signaling cascade (TLR4, TLR8, PELI2, IRAK3) were under-
expressed as well; TLR/MyD88 signaling plays a key role in experimental models of 
transplantation tolerance,243,244 and TLR4 inactivation protects against GVHD.245 Several 
important cell signaling molecules were over-expressed: TOX is known to be involved in CD4 T 
cell lineage development, and important for Treg and CD1d-dependent NKT cells.246 LAG3, a 
major negative regulator of CD4 and CD8 T cell activation and important for Treg homeostasis, 
function, and inhibition of DC activation, was over-expressed.247-249 Conversely, SOCS2 
(involved in DC maturation),250 and beta arrestin 1 (involved in T cell activation, enhances 
transcription of IFN-γ and IL-17; increased in primary biliary cirrhosis patients)251,252 were 
decreased. Among cytokines and their receptors, TOL patients had decreased expression of IL-
13RA (IL-13 induces B cell proliferation and differentiation, and is expressed on Th17 cells), as 
well as BAFF and APRIL (major B cell activating TNF ligand family members implicated in 
human chronic GVHD).122,124,253 Conversely, TGFBR3 (TGF-β co-receptor relevant to TGF-β 
receptor complex stability and signaling),254 expression was increased. As well, IFN-γ was 
increased in TOL patients. This has been demonstrated to have both pro-inflammatory and 
immune regulatory actions,255 importance in migration of Treg and conventional T cells to GVHD 
target organs,256 and to mediate immune regulatory function in FoxP3+ Tregs in experimental 
GVHD.257 In keeping with published data in solid organ transplantation tolerance, TOL patients 
had decreased expression of anti-apoptotic (DAPK1, SOD2, PPT1, SOCS2, VNN1, SMAD1, 
GSN), and increased expression of pro-apoptotic (GZMH, PLEKHF1) mediators, as well as 
involvement of cell cycle control genes. 
Differentially expressed genes in the non-TOL group were strongly associated with NK 
cell cytotoxicity, antigen presentation, lymphocyte proliferation, and cell cycle and apoptosis 
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cellular process networks:  Multiple NK cell/lectin receptors (By55/CD160, KLRK1, KLRD1, 
KLRC4, KLRC3, KLRC2) and cytolytic effectors (granulysin, and granzymes A, B, and K) were 
under-expressed in the non-TOL group with respect to both TOL and control subjects.172 
Tolerogenic activity of NK cells has been related to killing of activated T cells, production of IL-
10, competition with CD8+ T effectors for IL-15, and killing of antigen-presenting DC.258 While 
we did not detect decrease in absolute NK cell numbers, these gene expression findings are in 
keeping with a cohesive finding of NK deficiency in human chronic GVHD,259,260 as well as the 
primacy of NK-associated gene expression changes (including specifically CD160 and NKG7) in 
distinguishing tolerant vs. non-tolerant liver transplant recipients in Martinez-Llordella, et al.195 
There was over-expression of TLR/MyD88 signaling (DUSP6, TLR1), complement receptors 
(VSIG4, CR1, CD93), and Fc receptors (FCGR1B, FCER1G), again highlighting the important 
role of the innate immune system. Among signaling mediators, GAPT (GRB2-binding adaptor 
protein associated with B cell activation),261 and MNDA (myeloid cell nuclear differentiation 
antigen expressed in cells of the granulocyte-monocyte lineage and involved in response to 
interferon) were increased; interferon-inducible Ifi200-family genes (including MNDA) have been 
associated with autoimmune disorders, including systemic lupus erythematosis.262,263 In contrast 
to TOL, the non-TOL patients had increased BAFF, and decreased TGFBR3. In keeping with 
findings after solid organ transplantation, non-TOL patients had increased expression of anti-
apoptotic (SOD2, CARD16) and decreased expression of pro-apoptotic (GZMB, GZMA, DLG5) 
mediators, and involvement of molecules relevant to cell cycle control.  
 
Unifying tolerance model:  While diverse mechanisms have been established for 
immune tolerance development, the experimental data presented here highlight the central role 
of dendritic cell (DC) and natural killer (NK) cell interaction. Major supporting differential gene 
expression data for this hypothesis is presented in table 9. These data are consistent with 
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established bi-directional DC – NK interactions that shape DC and NK activity and 
subsequently, adaptive immune responses. A cohesive model supports the following: In the 
immune tolerant state, DC maturation and pro-inflammatory cytokine expression is decreased, 
thus dampening B and T cell adaptive responses. The major down-regulation of TLR (TLR4, 
TLR8, allied signaling molecules) is supportive of a tolerogenic program in DC, as well as other 
cell types that express TLR (e.g. B and T lymphocytes). Immature DC are susceptible to NK-
mediated cytotoxicity, as demonstrated by NK degranulation (NKG7). In the non-tolerant state, 
TLR signaling and DC maturation are increased leading to productive B and T cell responses, 
and NK cytotoxicity is impaired with reduced activating NK lectin receptors and cytotoxicity 
effectors. Decreased NKG2A signaling in particular may result in diverse effects that support 
this paradigm (table 9).  
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Table 9:  Dendritic cell and Natural Killer cell interaction: A unifying hypothesis for the observed 
immune tolerance-associated differential gene expression  
 
 
 Immune Tolerant 
State 
 Non-tolerant 
(GVHD) State 
 
DC ↓TLR4, ↓TLR8 
↓LILR, ↓SOCS2 
↑LAG3 
- ↓DC maturation, co-
stimulatory molecule 
and pro-inflammatory 
cytokine expression171 
   
- Immature DC lysed by 
NK  
 
↑TLR1, ↑DUSP6 
↑ VSIG4, ↑CR1, ↑CD93 
 
- ↑ DC 
maturation, co-
stimulatory 
molecule and 
pro-
inflammatory 
cytokine 
ŊŊ
171  
- Mature DC 
not lysed by 
NK, stimulating 
adaptive 
immune 
response 
NK  ↑ NKG7 ↑ Target cell-induced 
NK cell 
degranulation264 
↓NKG2C/D/E/F, 
↓CD160 
↓GZMA/B/K, ↓GNLY 
 
 
 
↓NKG2 A 
(↓IL-2RB) 
- ↓ Activating 
NK receptors 
- ↓ Cytolytic 
effectors  
 
- * 
B 
cell 
 
↑FCRL3 
↓LILR, ↓IL13RA, ↓TLR 
↓BAFF, ↓APRIL 
 
- ↓ BCR signaling, 
activation, and survival 
↑GAPT 
↑BAFF 
- ↑B cell 
activation, 
survival 
T 
cell 
↑TGFBR3 
↑LAG3, ↓ARRB1, 
↑TOX 
- tolerogenic profile 
(↓activation, 
↓Th1/Th17, ↑Treg)  
↓TGFBR3 - Decreased 
TGF-β 
signaling/pro-
inflammatory 
state 
 
*Diverse potential mechanisms: (1) CD94/NKG2A+KIR- NK mediate immature DC killing (NKG2A+KIR-
IL2-R+ CD56bright NK subset may kill immature self-DC and express regulatory cytokines including IL-10) ; 
(2) murine Qa-1 (HLA-E in humans) binding of NKG2A regulates activity of CD8+ T cells, NK, and NKT; 
(3) NKG2A in human γδ T cells inhibits effector function; (4) NKG2A-DC mediated induction of 
CD4+CD25+ Treg. 
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CHAPTER 4: 
 
CONCLUSION AND DISCUSSION 
 
 
The desired end result of HCT is cure of the treated hematologic malignancy or disorder, 
effective prevention and therapy of GVHD, and development of immune tolerance. Major 
shortcomings exist in current practice:  Existing pharmacologic immune suppressive GVHD 
prophylaxis regimens do not effectively prevent acute GVHD for many patients, severe acute 
GVHD is poorly responsive to therapy, and the majority will experience chronic GVHD. Finally, 
clinical judgment does not accurately identify the development of immune tolerance, practice 
surrounding discontinuation of immune suppression (IS) is empiric, and GVHD commonly 
develops or reoccurs in the setting of attempted IS discontinuation. These limitations undermine 
the potential of HCT as an otherwise curative therapy. The presented data directly address 
these areas of need, and suggest next steps in this line of investigation that promise to improve 
HCT outcomes. 
We conducted a randomized trial comparing SIR/TAC vs. the commonly accepted 
standard MTX/TAC.238 We demonstrated that SIR/TAC led to reduction in grade II-IV acute 
GVHD, however we did not observe significant reduction in grade III-IV acute GVHD, and 
benefit was restricted to reduction in GI acute GVHD (the most commonly represented organ 
site of acute GVHD involvement in this study). As well, over 40% of patients in the SIR/TAC arm 
experienced grade II-IV acute GVHD. Importantly, since completion of this study, a national 
BMT CTN phase III trial comparing SIR/TAC to MTX/TAC has shown only modest improvement 
in acute GVHD with SIR/TAC.265 Important differences in the CTN trial (restriction to sibling 
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donor transplants, different conditioning regimen, and shorter duration of SIR exposure post-
HCT) limit direct comparisons, however. These data speak to the need for additional advances 
in the field. We did observe, however, that prolonged administration of SIR was associated with 
significantly reduced incidence of NIH Consensus moderate to severe chronic GVHD. These 
findings are noteworthy, as previously published trials examining SIR/TAC (without this duration 
of SIR therapy post-HCT) have resulted in a greater burden of chronic GVHD.28,29 Most 
importantly, SIR/TAC supported the reconstitution of functional Treg and suppressed non-Treg 
CD4+ T cells after HCT. These prospective data advance knowledge of Treg reconstitution 
following clinical HCT beyond previously reported correlative studies,84,85 support the concept 
that sirolimus exerts suppression of non-Treg CD4+ cells,82  and indicate that the combination of 
SIR/TAC may serve as a platform for Treg adoptive therapy. However, as Treg are dependent 
on IL-2 signaling, we recognize that the concurrent administration of TAC may counter 
beneficial effects of SIR on Treg. While a calcineurin inhibitor-free regimen would be most 
attractive, current evidence does not support the feasibility of this approach for GVHD 
prophylaxis after HCT.266 Our team has developed a clinical trial testing the addition of low-dose 
subcutaneous IL-2 administration together with SIR/TAC (NCT01927120). This initial study may 
provide a foundation for subsequent investigation exploring whether elimination of TAC can be 
safely accomplished. Finally, as a direct extension of the presented work, we have developed 
technology to ex-vivo expand antigen-specific donor Treg,267 and will test escalating dose of 
donor Treg (on platform of SIR/TAC) as adoptive therapy for GVHD prevention in a phase I trial 
(NCT01795573). This trial will provide a first-in-human test of the safety, clinical efficacy, and 
biologic activity of ex-vivo expanded antigen-specific donor Treg delivered for prevention of 
human GVHD. In total, these efforts promise to expand our scientific understanding, and may 
more effectively prevent GVHD and facilitate development of immune tolerance. 
74 
 
In the context of the parent randomized trial comparison of SIR/TAC vs. MTX/TAC, we 
have examined tissue-infiltrating CD4+ T cell subsets to discern mechanisms of failure. These 
data implicate Th17 cells in human GVHD target organs, support a reduction in Th17 under SIR 
treatment, and demonstrate that tissue-resident Th17 are associated with GVHD severity and 
refractoriness to standard primary GVHD therapy. Of note, we found no significant association 
of tissue-resident Th1 or Treg with GVHD prophylaxis type, pathologic or clinical severity grade 
of GVHD, or refractoriness to primary GVHD therapy. Our data are in keeping with evidence 
that supports a pathogenic role for Th17 in GVHD, and support the concept that interventions to 
reduce Th17 in vivo may lead to benefit in GVHD prevention and control. Through this and allied 
clinical and pre-clinical investigation (data not shown, manuscript under review), we have 
assembled a body of evidence implicating the STAT3/RORy/Th17 axis in GVHD development 
and severity: In addition to the described human GVHD tissue work, we have demonstrated that 
STAT3 phosphorylation is significantly increased in CD4+ T-cells among human HCT recipients 
prior to the onset of grade II-IV GVHD. As well, we demonstrate that concurrent neutralization of 
TORC1 and STAT3 with rapamycin and S3I-201 (a STAT3 small molecule inhibitor) optimally 
suppresses RORy expression, and that rapamycin-resistant T-cell proliferation can be inhibited 
by STAT3 blockade.  Building from this concept, we have tested the activity of the IL-12/23p40 
neutralizing antibody ustekinumab in the setting of advanced steroid-refractory acute GVHD,268 
and are currently conducting a placebo-controlled GVHD prevention trial that tests the addition 
of this agent to the SIR/TAC platform (NCT01713400). This trial promises to discern whether IL-
12/23p40 neutralization will skew CD4+ T cell differentiation in vivo (diminish Th1 and Th17, 
augment Treg) and lead to beneficial reduction in GVHD.  
Investigation into mechanisms of human immune tolerance after HCT is highly relevant 
to the body of work described above: There are currently no validated clinical or biologic 
determinants of immune tolerance after HCT, the required duration of IS therapy for any 
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individual patient is not known, clinical judgment can’t distinguish drug-suppressed immune 
response from the development of donor-recipient immune tolerance, and clinical practice of IS 
discontinuation is empiric and fraught with a large burden of resultant GVHD (the major 
manifestation of donor-recipient immune intolerance). Any advances in prevention of GVHD are 
undermined by the development or recurrence of GVHD in the context of attempted IS 
withdrawal, however this phenomenon has been poorly studied to date. In a cross-sectional 
study, we have examined differential gene expression among tolerant, non-tolerant, and healthy 
control subjects to address this need. In this initial experiment, we have demonstrated that 
differential gene expression can provide mechanistic insight into immune tolerance, and that this 
data can be utilized to develop an accurate phenotypic classifier. Many of these candidates 
appear to have great biologic relevance based on previously published work in immune 
tolerance, and some are actionable targets of existing therapeutic agents. Despite inclusion of 
healthy controls and advanced computational work to stringently refine a list of informative 
candidate genes, we acknowledge that this single cross-sectional design does not completely 
recapitulate the clinical scenario of attempted IS withdrawal. A prospective trial (samples drawn 
at time of IS discontinuation and serial subsequent samples with observation for development of 
GVHD) is planned that will address this question further, and future work will investigate both 
advanced technology (RNA deep sequencing) and explore cell subset-specific gene expression 
changes.  
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